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Summary 
K-Ras is a key signaling molecule regulating central biological processes like proliferation, 
polarization and survival, and is essential in the control of tissue homeostasis. Constitutive 
active K-Ras mutations are found in 40% of all colorectal cancers (CRC) contributing to 
tumor development, progression and therapy resistance. Despite constant efforts there 
are no targeted therapies available for K-Ras mutated CRC thus far.  
To develop new, mechanism-based treatment strategies the contribution of oncogenic Ras 
to transformation and therapy resistance has to be understood in detail. For this purpose, 
the human epithelial colorectal adenocarcinoma cell line Caco-2 was used as a model in 
this thesis. Cultured Caco-2 cells represent an early stage of CRC. They express wild-type 
K-Ras and have no further mutations in downstream Ras signaling pathways. Seeded into 
a three-dimensional culture system, Caco-2 cells are able to polarize, partly recapitulating 
the morphological features of the normal colorectal epithelium. By introducing an 
oncogenic K-Ras variant (G12V) in this organotypic model system, using an inducible 
expression system, two new aspects of oncogenic Ras signaling could be described for the 
first time: 
Firstly, the acute expression of K-RasG12V disrupted polarized morphogenesis of Caco-2 
grown in 3D culture. I was able to identify a novel autocrine signaling loop that mediated 
the hyperproliferation and loss of cell polarity induced by K-RasG12V expression, which 
involved the receptor tyrosine kinase ErbB3 and transcriptional upregulation of its ligand 
heregulin (HRG).  
Secondly, in Caco-2 3D cultures, K-RasG12V expression led to resistance against a targeted 
single-chain TRAIL molecule (Db-scTRAIL) comprising an ErbB1 blocking moiety derived 
from cetuximab and three TRAIL monomers. Here, I identified a resistance mechanism 
triggered by K-RasG12V involving the upregulation of the anti-apoptotic proteins cIAP1/2. 
The combination of Db-scTRAIL with a new Smac mimetic (SM83) was able to override this 
resistance not only in the Caco-2 model but also in additional Ras-mutated CRC cell lines.  
Taken together these findings provide the basis for a new rational approach: combining 
ErbB3 blockade in Ras mutant CRC with an apoptosis inducing TRAIL molecule plus a 
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sensitizing Smac mimetic. This combination might efficiently block the autocrine Ras-HRG-
ErbB3 loop and therefore suppress transformation whilst simultaneously inducing 
apoptosis.
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Zusammenfassung 
K-Ras ist ein Schlüsselmolekül in zentralen biologischen Prozessen wie Proliferation, 
Polarisation und Überleben und trägt essentiell zur Gewebehomöostase bei. Dauerhaft 
aktives Ras ist in 40 % der Kolorektalkarzinome nachweisbar und führt zu 
Tumorentstehung, Progression und Therapieresistenz. Trotz stetiger Forschung gibt es bis 
heute keine ziel-gerichtete Therapie für K-Ras mutierten Darmkrebs. Für die Entwicklung 
neuer Ansätze muss die Rolle von Ras in der Krebsentstehung und Therapieresistenz 
besser verstanden werden. Zu diesem Zweck wurde in der vorliegenden Arbeit die Zelllinie 
Caco-2, eine aus humanen Epithel-zellen des Kolons gewonnene Adenokarzinomlinie, als 
Modell verwendet. Diese Zellen exprimieren natives K-Ras und weisen keine weiteren 
Mutationen in Ras assoziierten Signal-wegen auf. Eine Besonderheit der Caco-2 Zellen ist 
ihr polares Wachstum in 3D Zellkulturen, wodurch sie den normalen Aufbau des 
Darmepithels nachbilden. Durch die induzierbare Expression einer K-Ras Variante (G12V) 
in diesem Zellsystem konnten in meiner Arbeit zwei neue Aspekte von onkogenem K-Ras 
beschrieben werden: 
Erstens, störte die Expression von K-RasG12V das polare Wachstum der Caco-2 Zellen in der 
3D-Kultur. Ich konnte einen hierfür verantwortlichen autokrinen Regelkreis identifizieren, 
welcher die Rezeptortyrosinkinase ErbB3 und die Hochregulierung des Liganden Heregulin 
(HRG) beinhaltete. Dieser Regelkreis ist für die durch K-RasG12V vermittelte, gesteigerte 
Proliferation sowie den Verlust der Zellpolarität verantwortlich. 
Zweitens, induzierte die Expression von K-RasG12V in 3D-Kulturen Resistenz gegenüber 
einem zielgerichteten TRAIL-Molekül, das eine ErbB1-inhibierende Einheit, abgeleitet von 
cetuximab, und eine Kette von drei TRAIL Monomeren beinhaltet (Db-scTRAIL). Für die 
durch K-RasG12V aus-gelöste Resistenz konnte ich die transkriptionelle Hochregulierung der 
anti-apoptotischen Proteine cIAP1/2 als veranwtortlich identifizieren, deren Inhibition 
durch ein neues Smac-Mimetikum die Resistenz gegenüber Db-scTRAIL überwinden 
konnte. 
Zusammenfassend schlage ich aufgrund dieser Ergebnisse einen neuen rationalen 
Therapie-ansatz für Ras-mutierten Darmkrebs vor, der aus der Kombination von ErbB3-
Inhibition mit einem Apoptose-induzierenden TRAIL-Molekül plus eines sensitivierenden 
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Smac-Mimetikum besteht. Diese Kombination könnte effizient die autokrine Ras-HRG-
ErbB3 Signalkette unterbrechen und somit die Tumorentstehung inhibieren und 
gleichzeitig Zelltod induzieren. 
1 
I .  I N T R O D U C T I O N
1. CANCER
Cancer is the leading cause of death in the developed countries. Every year 14 million new 
cases of cancer are diagnosed and 8.2 million cancer related deaths are counted 
worldwide [1]. The most common cancerous disease is lung cancer (30%), followed by 
breast (15%) or prostate cancer (10%) and colorectal cancer (8%).  
1.1. Hallmarks of cancer 
The term “cancer” describes a very heterogeneous and complex disease with specific 
causes and treatment options for each cancer entity. There are more than 100 types of 
cancer that often can be divided into specific subtypes, showing the complexity and 
difficulty to understand this disease and to develop evidence based treatment strategies 
for each cancer type.  
Figure I-1: Hallmarks of cancer. Illustration of the six hallmarks of cancer proposed by Hanahan 
and Weinberg in 2000. These hallmarks include deregulated cellular processes contributing to 
tumor development, progression and metastasis in almost all cancer types. [2] 
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But there are some common characteristics among all neoplastic diseases. Hanahan and 
Weinberg defined in the year 2000 the “hallmarks of cancer” [3].  
They proposed that cancerous tissues are not only uncontrolled growing cell mass, but 
reflect a complex interplay between different types of cancer cells and non-transformed 
cells. These cells all contribute in different ways to sustained proliferative signaling, 
evasion of growth suppression, resistance to cell death, enabled replicative immortality, 
induction of angiogenesis, and activation of invasion. These mechanisms lead to 
uncontrolled growth, deterioration of adjacent tissue and organs, and finally spreading 
throughout the whole body and formation of distant metastasis (Fig. I-1). These 
characteristics are based on genetic mutations of the tumor cells and are supported by the 
surrounding tissue, the tumor stroma cells, together creating a favorable milieu known as 
the tumor micro-environment [2]. It has been realized that the tumor stroma not only 
plays an important role in cancer progression but also in the development of therapy 
resistance. Therefore, targeting the tumor stroma is now being considered as a new anti-
cancer treatment strategy [4,5].  
2. COLORECTAL CANCER
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. With 
approximately 1.36 million new cases diagnosed annually it is the second most common 
cancer type in the Western world and accounts for 694,000 related deaths per year 
recorded worldwide [6]. Beyond genetic mutations the dominant causative factors are still 
diet and lifestyle [7]. Especially in patients with advanced, metastatic CRC survival rates 
are low (11%) and recurrence rates high (up to 50%) [8,9]. Due to better screening 
programs and early removal of precancerous lesions (polyps) the incidence of CRC has 
declined in the last 10 years.  
2.1. Development of CRC 
Tumorigenesis in general can be described as a multistep process. In CRC a sequence of 
specific mutations leads to the transformation of the normal intestinal tissue into 
malignant neoplasms. In 1990 Fearon and Vogelstein specified the mutated genes in 
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essential pathways, responsible for the development of CRC [10]. This process is also 
known as the adenoma-carcinoma sequence (Fig. I-2). 
Genomic instability is considered as the starting point of CRC development. The loss of 
DNA-repair functions by mutations in the mismatch repair genes (MMR) or alterations in 
the activation of MMR genes by changes in their methylation patterns can lead to 
microsatellite instability (MSI). Chromosomal instability (CIN) is the second origin of 
genomic instability and is caused by loss of cell cycle control genes like CDC4 [11]. Both – 
MSI or CIN – can result in the physical loss of tumor-suppressor genes during tumor 
progression, such as APC, TP53, and TGFBR2/SMAD [12].  
 
Figure I-2: Adenoma-carcinoma sequence. Genetic alterations in signaling pathways that are 
involved in the progression from the adenoma stage of CRC to advanced, metastatic CRC. 
Microsatellite instability (MSI) initiated by mismatch-repair (MMR) defects and chromosomal 
instability (CIN) lead to further loss-of-function (red) or gain-of-function (green) mutations within 
genes like APC, KRAS, PIK3CA, TP53, TGFBR2. See text for further details. [13]  
The APC/Wnt/β-catenin pathway for example regulates cell cycle progression and 
contributes to the differentiation and migration process of stem cells during tissue 
regeneration. Loss of APC is inevitable for tumor initiation and the development of benign 
polyps in the colon. p53, encoded by the TP53 gene, is a transcription factor that regulates 
the expression of several proteins important for cell cycle control. In cells with defect 
MMR p53 can induce apoptosis – the programmed cell death – by activation of the pro-
apoptotic protein BAX in order to remove degenerated cells from the body. So p53 
mutations lead to cell survival and tumor progression [13]. The mutational inhibition of 
growth factor signaling by TGF-β is induced by alterations in the TGF-β receptor 2 
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(TGFBR2) or the downstream effector SMAD4, a third example for loss-of-function 
mutations in the subsequent progress of CRC [13]. TGF-β serves as a growth suppressor in 
the normal intestinal tissue and orchestrates processes like proliferation, differentiation, 
migration and apoptosis. In MSI positive CRC tumors mutations in the TGFBR2 induce TGF-
β resistance, resulting in hyperproliferation and the transition into an invasive and 
metastatic tumor state (mCRC) [14].  
Beyond loss-of-function mutations, activation of oncogenic pathways plays a key role in 
the transition of adenomas to carcinomas. Activation of growth factor signaling pathways 
occur at several stages of the signaling cascade. Mutations within the mitogen-activated 
protein kinase (MAPK) signaling pathway by constitutive activation of the small GTPase 
Ras or the kinase Raf lead to growth factor independence and sustained cell proliferation. 
Activation of the phosphatidylinositol 3-kinase (PI3K) pathway can be observed by 
constitutive activation of the catalytic subunit of the PI3K (PIK3CA) or by inactivation of 
the phosphatase PTEN that negatively regulates PI3K (Fig. I-4) [12]. 
Taken together, the progression of CRC from benign polyps (adenomas) to invasive 
carcinomas is driven mainly by alterations in growth factor signaling, regulation of 
differentiation and induction of cell death. 
2.2. Growth factor signaling 
Inadequate activation of growth factor signaling pathways can be caused by constitutive 
activation or overexpression of oncogenes or depletion/inhibition of tumor-suppressors, 
resulting in uncontrolled and sustained cell growth and evasion of cell death [3]. 
Two important growth factor signaling pathways are the ERK/MAPK pathway and the 
AKT/PI3K pathway (Fig I-4) that are activated by mutations in most neoplasms [15]. Both 
are important for adequate proliferation. In addition the AKT/PI3K pathway negatively 
controls apoptosis and leads to enhanced survival.  
ErbB receptor signaling 
In non-transformed cells both growth factor signaling pathways are tightly controlled. 
Activation only occurs after binding of ligands (growth factors) to their specific receptor at 
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the cell surface. One important receptor family is the ErbB family of receptors, which 
comprises ErbB1/EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. These receptor 
tyrosine kinases (RTK) possess an extracellular ligand-binding domain, a single membrane 
spanning region, and a cytoplasmic tyrosine kinase domain (Fig. I-3) [16,17]. Upon binding 
of the specific peptide ligand, the receptors homo- and heterodimerize. This leads to 
receptor activation and transphosphorylation of specific tyrosines within the cytoplasmic 
tail. These phosphotyrosines provide docking sites for intracellular signaling molecules 
that trigger the activation of the MAPK and PI3K pathways, which mediate biological 
responses such as proliferation, migration and survival (Fig. I-4) [17,18]. 
 
Figure I-3: ErbB receptor family. The ErbB receptor family comprises the four receptor tyrosine 
kinases ErbB1/EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Several peptide ligands can 
activate the receptors by binding to the extracellular domain of their corresponding receptors, 
resulting in homo- or heterodimerization and transphosphorylation of the intracellular tail and 
consequent downstream signaling. (Adapted from [17,19]) 
ErbB receptors are activated by a variety of different peptide ligands. ErbB1 is potently 
activated by the growth factors EGF and TGF-α. Although ErbB2 has no direct ligand, it 
readily dimerizes with the other ErbB receptors due to its constitutively active 
conformation [20]. ErbB3 is unique in that it has an impaired kinase domain, but in a 
heterodimer with a signaling competent ErbB family member ErbB3 becomes 
phosphorylated and can serve as a signaling platform [21,22]. The presence of several 
consensus sites for the p85 subunit of PI3K mediates the potent induction of AKT/PI3K 
signaling by phosphorylated ErbB3 [22,23]. The heregulins (HRGs; also known as 
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neuregulins (NRGs)), a family of peptide ligands comprising more than 20 different 
isoforms encoded by the genes NRG1-4, specifically bind ErbB3 and ErbB4 (Fig. I-3) 
[19,24]. Malignant activation of ErbB receptor signaling can be caused by mutations of the 
receptors or by changes in the expression level. Overexpression of ErbB1 is observable in 
head and neck cancer, esophageal cancer, and colorectal cancer. ERBB3 somatic 
mutations can be found in 11% of colon and gastric cancers [25]. The ligands are also 
found to be upregulated and contribute to hyperproliferation and treatment escape, 
either by autocrine mechanisms or paracrine signaling by the surrounding stroma cells 
[26,27]. In cancer different mechanisms can contribute to autocrine signals: firstly, cell 
polarity and therefore the separation between apical and basolateral membranes of 
epithelial cells can be compromised [28] and secondly, tumor-specific changes in gene 
expression can result in the complementation of cognate ligand-receptor pairs in the 
transformed tissue [29,30].  
Downstream effector proteins of ErbB receptor signaling 
RTK signaling converges at the level of the protein Ras, a master regulator of several 
crucial signaling pathways in the cell. Amongst these pathways are the MAPK and PI3K 
pathways, regulating not only proliferation and apoptosis but also tissue organization 
[31,32]. This makes Ras a major proto-oncogene. Ras proteins belong to the family of 
small GTPases and comprise three members, H-Ras, K-Ras and N-Ras. Ras proteins cycle 
between an active GTP-bound and an inactive GDP-bound state. The transition between 
these stages is regulated by guanine nucleotide exchange factors (GEFs) that facilitate the 
activation of Ras and GTPase activating proteins (GAPs) that enhance the intrinsic GTPase 
function of Ras and thus inactivate the protein. Activated RTKs serve as docking sites for 
the adaptor protein GRB2, that recruits the GEF SOS to the plasma membrane where it 
activates the membrane bound Ras protein by exchange of GDP to GTP. Activated Ras 
then binds to the serine/threonine kinase Raf. This relocation of Raf to the plasma 
membrane activates the kinase, which then phosphorylates and activates MEK, which in 
turn phosphorylates and activates ERK. ERK then phosphorylates and activates 
transcription factors that promote cell cycle progression and proliferation (Fig. I-4) [33]. 
Additionally active Ras can directly interact with the catalytic subunit of PI3K leading to 
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the activation of the serine/threonine kinase AKT, which has a strong anti-apoptotic 
function and is crucial for cell survival (Fig. I-4).  
 
Figure I-4: ErbB receptor signaling and corresponding downstream signaling pathways. Homo- 
or heterodimerization upon ligand binding leads to receptor activation, followed by 
transphosphorylation (P) of tyrosines (Y) in the intracellular domain. These p-tyrosines serve as 
docking site for adaptor proteins like GRB2 or for the p85 regulatory subunit of PI3K. Subsequent 
activation of downstream signaling molecules activates the MAPK (sand) or PI3K (green) 
pathways. See text for further details. (Adapted from [18,33]) 
Mutated Ras is one of the main drivers of growth factor independent signaling and is 
constitutively active due to specific point mutations. The most frequent mutations in CRC 
occur at codon 12 or 13 (predominantly G12D and G12V or G13D conversion) [34]. Nearly 
40% of all CRC cases harbor activating mutations in the KRAS gene [8,35,36]. Another 
common oncogene in the same pathway is B-Raf, mutated in 12% of all CRC patients. 
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Mutations in K-Ras and B-Raf are mutually exclusive, whereas mutations in K-Ras and PI3K 
can be detected in the same CRC cell [37].  
2.3. Differentiation and Polarization 
Polarization is a prerequisite for tissue homeostasis and normal function. Through the 
restriction of protein distribution within the cell, different compartments and cell poles 
are defined. This is achieved by a diffusion barrier built by tight junctions (TJ) comprising 
proteins like ZO-1 and Occludins. Furthermore, intercellular adhesion via adherens 
junctions (AJ) is important to maintain tissue organization and cell-cell communication. AJ 
comprise for instance the protein E-cadherin. The establishment of these junctions and 
the polarized phenotype is regulated by three polarity complexes called Crumbs, Par and 
the Scribble complex. All of them are regulated by a well-orchestrated interplay of 
different pathways [38]. The main regulators of the underlying cellular processes are small 
GTPases of the Ras and Rho families, the latter controlling cytoskeleton rearrangement 
and therefore cell shape and movement [32] as well as membrane trafficking [39].  
In the normal intestinal epithelium the apical-basal polarity of the epithelial cells has an 
important barrier function. It distinguishes the inside, facing the basal membrane (basal 
side), and the outside (apical side), representing the outer surface of this exocrine tissues 
(Fig. I-5). The controlled excretion of digestive proteases into the gut lumen and the 
absorption of nutrients at the brush border into the cells and the transport towards 
adjacent tissues and the blood vessels is one example for the functional difference of the 
apical and basal side of the intestinal tissue (Fig. I-5). Spatially restricted protein and 
receptor distribution by site directed trafficking and excretion of ligands and the 
maintenance of this asymmetry are also important for proper signal transduction. In 
epithelia that express both, the ligands and receptors, the tight junctions separate the 
different subcellular membranes, the receptors and cognate ligands are directed to, 
thereby preventing unwanted autocrine stimulation [40].  
Loss of polarity is a hallmark and precondition of cancer [38]. 80% of all malignancies arise 
from epithelial tissues like the intestine. Several alterations are known to interfere with 
proper polarization and tissue architecture. Activation of ErbB2 together with oncogenic 
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expression of mutated Ras is known to induce tissue disorganization and loss of polarity in 
cancer cell lines [41,42]. Mutated Ras in combination with loss of polarity proteins like 
Scribble also shows the necessity of cooperation between two oncogenic events like loss 
of tumor-suppressors and constitutive activation of Ras to induce tissue depolarization in 
CRC models [43,44]. 
 
Figure I-5: The intestinal epithelium. The barrier between the lumen of the colon and the 
adjacent tissue is built by a layer of epithelial cells. At the macro level this tissue is organized in 
finger-like projections that extend into the lumen, the villi, and the crypts with different types of 
cells like goblet cells, which produce mucus, or stem cells responsible for renewal of the tissue. 
The intercellular barrier between the epithelial cells is maintained by tight junctions (TJ). Side-
directed trafficking generates further functional differences between the apical and basal side of 
the cells. See text for further details. (Adapted from [32,45,46]) 
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2.4. Apoptosis 
Programmed cell death, also known as apoptosis, ensures tissue homeostasis by depletion 
of damaged or unnecessary cells and protects the organism against malignant 
transformation by eliminating the affected cells, if repair is not possible. Dysregulation of 
apoptosis often leads to cancer development or therapy resistance. Once activated, the 
apoptotic program leads to morphological changes like chromatin condensation, nuclear 
fragmentation and formation of so-called apoptotic bodies that can be engulfed by 
phagocytic cells [47]. There are two major pathways controlling the apoptotic machinery: 
the extrinsic and the intrinsic (Fig. I-7), both converge in the activation of caspases 
(cysteine aspartyl-specific proteases) that cleave key cellular proteins, degrade the cellular 
structure and irrevocably induce cell death [47]. 
The extrinsic pathway can be triggered by binding of death ligands to their receptor, 
activating the downstream apoptotic signaling cascade. One of these ligands is TRAIL (TNF-
related apoptosis-inducing ligand), a member of the TNF superfamily (tumor necrosis 
factor). It forms active homotrimers that crosslink TRAIL receptors on the cell surface 
(Fig. I-6) [48]. Oligomerization of the TRAIL receptors initiates the recruitment of adaptor 
proteins like FADD (Fas-associated death domain protein) and the formation of the death-
inducing signaling complex-II. This ultimately leads to the activation of initiator caspase 8 
and 10 and consecutive activation of effector caspase 3, 6 and 7, resulting in apoptotic cell 
death (Fig. I-7) [49]. There are four known TRAIL receptors, the death receptors TRAILR1 
(DR4) and TRAILR2 (DR5) and two decoy receptors TRAILR3 (DcR1) and TRAILR4 (DcR3) 
that are not signaling competent and are considered as antagonistic receptors [50].  
The intrinsic apoptotic pathway can be triggered by DNA damage or growth factor 
deprivation. These internal stimuli activate the pro-apoptotic proteins BAX and BAK that 
form pores in the outer mitochondrial wall and release cytochrome-c from the 
intermembrane space of mitochondria [47]. Cytochrome-c release activates APAF-1, which 
forms together with caspase 9 the so-called apoptosome. Within this structure caspase 9 
autoactivates and further activates the effector caspase 3 and 7 by proteolytic cleavage. 
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Figure I-6: TRAIL and its receptors. TRAIL is a homotrimeric ligand binding to the death receptors 
(DR) leading to receptor trimerization an essential step in receptor activation. The TRAIL 
receptors TRAILR1 (DR4) and TRAILR2 (DR5) contain an intracellular death domain (DD), which is 
essential for apoptosis signaling. The decoy receptors TRAILR3 (DcR1) and TRAILR4 (DcR3) 
compete with DR4 and DR5 for binding to TRAIL and therefore counteract apoptosis induction. 
(Adapted from [51]) 
Both pathways are tightly regulated by the balance of pro- and anti-apoptotic proteins. 
Misregulation of this balance is a common escape mechanism of cancer cells to avoid 
clearance [47]. Inactivating mutations in the TRAIL receptors were described for lung 
cancer and gastric cancers [52]. Overexpression of the anti-apoptotic Bcl-2 protein, which 
inhibits the activation of BAX/BAK, is correlated with poor survival and therapy resistance 
in several cancers [53].  
Amplification of the inhibitors of apoptosis proteins (IAP) is also a common motif in cell 
death evasion by cancer cells. cIAP1 and cIAP2 are amplified in many carcinomas and 
considered as proto-oncogenes. They inhibit caspase activation by direct binding and thus 
block apoptosis [54]. Depletion of these IAPs can also result in anti-apoptotic signaling via 
activation of the NFκB pathway, which initiates the expression of several anti-apoptotic 
proteins like Bcl-2 or xIAP, showing the importance of a balanced level of these apoptosis 
modulating proteins [47]. 
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Figure I-7: Apoptotic signaling. There are two apoptosis inducing pathways, the extrinsic, 
activated by death inducing ligands like TRAIL, and the intrinsic, triggered by intracellular stress 
signals. Both pathways converge in the activation of caspases and the induction of cell death. See 
text for further details. (Adapted from [47,48]) 
3. CANCER THERAPY 
Treatment of cancerous diseases is as diverse and complex as the different cancer types 
and subtypes are. With growing knowledge of the underlying mechanisms of cancer 
development and progression new treatment options emerge. In 2011 Hanahan and 
Weinberg adapted their model of the “hallmarks of cancer” according to the development 
in cancer research (Fig. I-8) [2]. Besides new origins of cancer they also summarized how 
these processes can be exploited for treatment, for example by specific inhibition of 
growth factor signaling pathways or the activation of apoptosis in cancer cells or the 
activation of an anti-cancer immune response. 
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Figure I-8: Targeting the hallmarks of cancer. Drugs that interfere with each of the traditionally 
defined and new emerging hallmarks have been developed and are under clinical investigation or 
already have been approved for clinical use in treating certain forms of human cancer. The 
treatment options listed depict selected examples of target mechanisms and the related anti-
cancer agents . [2] 
3.1. Systemic intervention 
Because of the high proliferative capacity of most of the malignant neoplasms anti-
proliferative strategies are common treatment options. These involve chemotherapeutics 
that inhibit proliferation and kill hyperproliferative tissues. Another option is radiation, 
leading to DNA strand breaks that cannot be repaired by the tumor cells, as these have 
often lost their DNA repair capability - another hallmark of cancer [2,55].  
But the first option with the greatest chance for cure in cancer treatment is still the 
surgical removal of the tumor mass. Systemic therapies, like chemotherapy or radiation, 
are often used as neoadjuvant or concomitant therapies to reduce tumor mass 
beforehand or kill remaining and circulating tumor cells after surgery.  
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3.2. Target specific compounds  
An important concept in modern tumor therapy is based on oncogene addiction. This 
means that tumor growth is dependent on one single mutated gene or a specific pathway. 
Blocking of this pathway or gene can lead to rapid response and tumor cell death. This 
knowledge led to a paradigm shift in treating cancer within the last two decades - from 
relative non-specific cytotoxic agents towards selective, mechanism-based targeted 
therapies [56]. There are specific inhibitors that attack each of the hallmarks of cancer 
proposed by Hanahan in 2011, including those that block receptor activation, restore cell 
cycle control, inhibit proliferation and invasion or induce apoptosis (Fig. I-8) [2]. 
Furthermore unleashing the immune system from inhibitory factors produced by the 
tumor or tumor stroma cells to support the innate anti-tumor response has evolved as a 
promising new approach, especially when combined with targeted therapies [57].  
Targeting the activation of proliferative pathways can be achieved by small molecules that 
interfere with RTK signaling by blocking the intrinsic tyrosine kinase activity [58]. A major 
problem in the treatment with these tyrosine kinase inhibitors (TKI) is the development of 
resistance during treatment either by evading the inhibitory effect by using another 
pathway or by acquired resistance against the TKIs due to secondary mutations in the 
tyrosine kinase domain [59]. 
Antibody-based therapy 
Higher specificity is achieved by targeting the RTKs on cancer cells with antibodies that are 
highly specific for their target antigen. The variable domains of the antibody can be 
designed to bind the extracellular ligand binding domain of a receptor (Fig. I-9, left). Such 
antibodies interfere with ligand induced receptor activation by allosteric or competitive 
inhibition. They can further trigger cytotoxic cellular responses upon recognition of the 
targeted cell by the immune system. But they can also serve as a delivery platform for 
cytotoxic agents that are coupled to the targeting moiety whereby the therapeutic 
accumulates at the tumor site [60].  
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Figure I-9: Targeting agents for cancer therapy. Antibodies like Immunoglobulin G (IgG) comprise 
a constant region and a variable domain, that itself contains hypervariable sequences, specific for 
its antigen. Diabody (Db) formats only contain the variable domains connected via short linker 
domains (black lines). ScTrail is a single polypeptide chain comprising three TRAIL monomers. 
Combining the diabody format with scTRAIL by genetic engineering lead to the targeted Db-
scTRAIL molecule used in this thesis.  
One of the best studied antibody targets is the ErbB receptor family. Antibodies against 
the extracellular domain of ErbB1 are for instance cetuximab or panitumumab. Cetuximab 
is a chimeric human-murine immunoglobulin (IgG1); this means that the constant domain 
of a human IgG is fused to the variable domains of a murine antibody targeting the 
extracellular domain of human ErbB1. Thereby the immune response against the murine 
part is alleviated, reducing cellular cytotoxicity [61]. Cetuximab competes with ErbB1 
ligands such as EGF or TGF-α for receptor binding, thereby repressing receptor 
phosphorylation and the activation of downstream signaling [8].  
3.3. Exploiting the apoptotic machinery for treatment 
Inducing apoptosis is an elegant way to kill tumor cells by exploiting the cell death 
machinery. TRAIL is a death ligand that induces apoptosis via the extrinsic pathway 
preferentially in tumor cells via the death receptors TRAILR1 and TRAILR2 [62]. Clinical 
trials using recombinant TRAIL confirmed the low toxicity to normal tissue, but therapeutic 
effects were insufficient compared to the results obtained in mouse models [48,63]. 
Additionally to the limited effects observed in clinical trials, several resistance mechanisms 
against TRAIL induced apoptosis have been described in tumor cell lines. Activation of pro-
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survival pathways via AKT and myc signaling or the expression of anti-apoptotic proteins 
like xIAP, cFlipL or Bcl-2 have been shown to block the induction of apoptosis [62,64]. 
To improve the antitumor activity of the recombinant TRAIL molecules a trimeric TRAIL 
was engineered at the institute [65]. It is well known that correct trimerization and zinc 
coordination of recombinant TRAIL is crucial for its biological activity [63]. Accordingly, the 
design of a single polypeptide chain comprising three TRAIL monomers (scTRAIL) 
enhanced the bioactivity of the recombinant molecule significantly [65]. Such molecules 
can further be fused to antibodies directed against tumor markers. It was previously 
shown that the fusion of scTRAIL to a single-chain antibody fragment (scFv) functionally 
mimicked natural membrane-bound TRAIL and that it was more effective than scTRAIL 
alone [65]. The introduction of a diabody configuration, based on the humanized variable 
regions of cetuximab (Db-scTRAIL) (Fig. I-9, right), resulted in an even higher bioactivity of 
recombinant TRAIL, both in vitro and in vivo [66].  
Apart from its tumor targeting effect, the ErbB1-directed antibody moiety contained 
within the Db-scTRAIL molecule might actively interfere with ErbB1 signaling.  
3.4. CRC treatment 
The current treatment of CRC is based on the stage of the diagnosed tumor. Early stage 
tumors can be removed by surgery alone and survival rates are high (75-95%). Once the 
tumor has spread and entered a metastatic stage, survival rates dramatically drop below 
10%. Here, systemic therapies are used like chemotherapy with fluorouracil, capecitabine 
or oxaliplatin. In addition to chemotherapy, targeted therapies have entered the clinic. 
Currently, the ErbB1 blocking antibodies cetuximab and panitumumab are approved for 
the treatment of metastatic CRC with wild-type K-Ras status in combination with 
chemotherapy or as a maintenance therapy in chemo-refractory tumors [67–70]. 
4. ONCOGENIC RAS IN CRC 
4.1. The role of oncogenic Ras in targeted therapy 
The proto-oncogene Ras plays a central role in uncoupling the activation of the MAPK and 
PI3K pathway from extracellular signaling cues such as growth factor binding to RTKs, 
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thereby conferring growth factor independence to mutant cells (Fig. I-4). Therefore, 
tumors with mutated K-Ras fail to respond to cetuximab and panitumumab. Thus, the use 
of anti-ErbB1 mAbs in CRC therapy is restricted to patients with no detectable K-Ras 
mutation [70,71]. Interestingly, compared to other K-Ras mutations DeBrook and 
colleagues could show a clear overall survival benefit of patients carrying a G13D mutation 
when treated with cetuximab [72].  
Despite constant efforts in pharmaceutical and academic research, direct targeting and 
inhibition of Ras is still a problem [73,74]. There are no targeted therapies currently 
available for patients with K-Ras mutant CRC [75,76]. In recent years, several small 
molecules that target Ras have been designed, which are now under clinical evaluation. 
There are four main strategies: Firstly, inhibition of the initial activation of Ras by GEF 
inhibitors. Unfortunately, these inhibitors most predominantly affect wild-type Ras. 
Secondly, an oncogene specific strategy to inhibit Ras activation is to covalently link a 
modified GDP to the thiol group of the newly introduced cysteine of K-RasG12C. Thus, the 
inactive GDP-bound form cannot be transposed into the active GTP-bound form. In cell 
culture models such covalent inhibitors showed high specificity for oncogenic Ras but also 
varying efficiency between different cell lines. Thirdly, the interaction of Ras and its 
effector proteins can be blocked by small molecules that bind to the surface of Ras. 
Inhibitors for Ras-PI3K or Ras-Raf interaction are currently under development [74]. 
Finally, the most promising approach is the inhibition of the farnesylation of Ras, which is 
crucial for the recruitment of Ras to the plasma membrane and thus for downstream 
signaling [73]. Up to now the clinical evaluation of these farnesyltransferase inhibitors 
could not recapitulate the effects observed in pre-clinical experiments. An important 
factor are resistance mechanisms by alternative membrane recruitment options of the 
cells, e.g. by palmitoylation [74].  
Instead of directly targeting Ras, inhibition of the downstream effectors has been 
investigated as well. The MAPK pathway is active in 50% of all CRC [33], due to aberrant 
activation of Ras or Raf. Several MEK inhibitors are in clinical trials and are effective in 
Ras/Raf-mutated tumors. B-Raf inhibition showed promising results especially in 
melanoma, for the treatment of which two MEK inhibitors were approved by the FDA 
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[77,78]. Despite the promising results in pre-clinical studies MEK inhibitors were not 
successful in K-Ras mutated CRC patients. Acquired resistance during MEK inhibitor 
treatment seems to be inevitable and involves the upregulation of the oncogene Ras itself 
and hyperactivation of ErbB3/PI3K/AKT signaling [76,79]. Additionally, the coexistence of 
PI3K mutations counteracts MEK inhibition. To combat these resistance mechanisms dual 
targeting of the MAPK and PI3K pathways entered clinical trials, including combinations of 
MEK/PI3K, MEK/mTOR or MEK/AKT inhibition (summarized in [76]). The results of these 
studies hopefully will result in new treatment options for K-Ras mutated CRC patients. 
4.2. The role of oncogenic Ras in apoptosis induction 
Beyond the clear contribution of Ras to oncogenesis and its capacity to potently activate 
proliferation, K-Ras mutations play a paradoxical role in apoptosis. Activation of the PI3K 
pathway by mutated Ras leads to phosphorylated AKT that inhibits the pro-apoptotic 
protein Bad. Furthermore, Ras can activate the transcription factor NFκB that promotes 
transcriptional upregulation of the anti-apoptotic proteins xIAP, cIAP2 and Bcl-2 [47,80]. 
Activation of the MAPK pathway was reported to play an anti- or pro-apoptotic role, 
depending on the cellular context [81,82]. Accordingly, the contribution of oncogenic Ras 
signaling to the sensitivity of tumor cells toward apoptosis-inducing ligands such as TRAIL 
is unclear. Drosopoulos et al. reported that the CRC cell line Caco-2, stably transfected 
with K-RasG12V, was sensitized to TRAIL induced apoptosis via a MEK dependent 
mechanism [83]. Similar results were obtained in lung cancer cell lines in vitro and in 
tumor xenografts in mice [84]. Additionally to its direct influence on PI3K and MAPK 
pathway, oncogenic Ras also leads to increased levels of growth factors, either by the 
elevated transcription of ErbB1 ligands [30,85] or release of membrane bound ligands by 
shedding in CRC cell lines [86]. This autocrine activation loop is associated with 
hyperproliferation and resistance to ErbB receptor targeting therapies as well as TRAIL 
mediated apoptosis [87].  
4.3. The role of oncogenic Ras in polarization 
Besides its role in hyperproliferation, evasion of growth suppression and resistance to 
apoptosis, mutant K-Ras plays an important role in another cancer hallmark: loss of 
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polarization. In a 3D cell culture model of colonic cyst formation, Magudia et al. described 
a role for K-RasG12V in basolateral polarity aberrations independent of its 
hyperproliferative effect. K-RasG12V expression in Caco-2 cells lead to unpolarized cysts 
with no lumen and the lack of tight junctions at the apical surface [88]. This defect in 
polarization could be observed already at the two cell stage, suggesting that uncontrolled 
Ras signaling can contribute to early stages of cancer development, showing the 
importance of oncogenic Ras in tumor initiation.  
4.4. Beyond oncogenic Ras 
Besides oncogenic Ras, several other genes within the RTK signaling pathways are found 
to be mutated, contributing to therapy resistance and tumor development. The 
overexpression of ErbB2/ErbB3 correlates with resistance to targeted therapies as well 
[89,90]. ErbB3, the unappreciated ErbB receptor, gained more and more attention 
regarding tumor development and therapy resistance in the last years [91–93]. 
Additionally, the receptor c-Met, a RTK that can also form dimers with the ErbB receptor 
family members, was reported to interfere with ErbB receptor blockade in CRC adding to 
the complex interplay of the different pathways [94,95]. Elevated levels of growth factors, 
derived from tumor cells or the microenvironment, such as NRG, contribute to tumor 
progression and resistance as well [96,97]. 
5. MODEL SYSTEMS FOR CRC RESEARCH 
5.1. Three-dimensional culture systems  
Studies in cell culture have been instrumental in delineating tumor-associated signaling 
pathways and genetic alterations on cellular behavior. Some cells, like the intestinal cell 
line Caco-2, show a certain level of polarization in 2D culture when grown in long-term 
cultures. The 2D cultures, however, lack the complex signaling processes initiated by 
interactions of the cells with the extracellular matrix (ECM). Cultivation of epithelial cells 
in a three-dimensional (3D) environment containing ECM components recapitulates better 
the conditions found in vivo [98,99]. There are several culture techniques ranging from 
scaffold-free hanging drop systems to matrix dependent cell cultures and even more 
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complex co-culturing systems, including ex vivo techniques like tissue organoids or slice 
cultures (Fig. I-10) (reviewed in [100,101]).  
 
Figure I-10: Cell culture models used in cancer research. Current cell culturing methods range 
from unstratified 2D cultures over scaffold dependent 3D cultures, where cells form fully 
polarized spheroids, to highly complex ex vivo organoid cultures or explant cultures of whole 
tissue slices. (for further details see reviews  [100,101]) 
In advanced 3D culture systems the establishment and maintenance of polarized 
morphology and the cell-matrix interaction can recapitulate the different steps of tumor 
initiation, progression and treatment response more precisely. Indeed several publications 
show the pivotal impact of the growth conditions on central cancer related pathways 
including cell cycle control [102], proliferation [98,99], apoptosis [103,104] or drug 
response [105]. That is why three-dimensional culture systems are also used for cancer 
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drug discovery [106] and should be considered as an important tool for translational 
cancer research and as an alternative for animal experiments.  
5.2. Three-dimensional culture models for CRC 
A common cellular model system for CRC is the Caco-2 cell line grown in a 3D matrix 
culture [101]. Caco-2 cells harbor mutations in APC, p53, and SMAD4, but are wild-type for 
the MAPK and PI3K pathways [88]. They furthermore express low levels of the receptors 
ErbB1, ErbB2 and ErbB3. Thus, Caco-2 cells are an ideal model for studying the effects of 
mutated K-Ras on transformation and treatment with ErbB receptor targeting agents in 
this setting. The 3D culture of Caco-2 cells mimics the in vivo situation of the intestinal 
epithelium more closely than 2D culture techniques and is comparably easy to handle 
[107]. Caco-2 cells grown under 3D conditions form fully differentiated polarized cysts 
with a basolateral side, contacting the surrounding ECM, and an apical side facing a fluid-
filled lumen (Fig. I-11). To culture Caco-2 cells in a 3D environment Lee et al. established a 
method called “on-top-culture” (Fig. I-10).  
Here, Caco-2 cells are seeded on top of a thin layer of matrix proteins, mimicking the basal 
membrane (e.g. composed of laminin, collagen IV, nidogen/enactin and proteoglycan) 
[98]. After 12 days of growth a distinct apical side forms, marked by F-actin accumulation, 
and a central fluid-filled lumen starts to develop. In contrast to the acini formation in the 
breast cancer cell line MCF10A lumen formation does not involve apoptosis, but rather 
requires cAMP signaling and activation of apical chloride channels accompanied by fluid 
efflux [107]. The maturation of the cysts can be facilitated by addition of choleratoxin 
(CTX) leading to faster water efflux into the lumen and thus shortened cell culture time.  
These early 3D cultures of Caco-2 cells already show apical formation of tight junctions 
(e.g. marked by ZO-1), important for lumen formation and spheroid maintenance. The 
basolateral side can be distinguished by the adherens junction protein E-cadherin. The 
polarity complexe PAR, comprising the protein aPKC (atypical protein kinase C) further 
accumulates at the apical pole of polarized cells. 
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Figure I-11: 3D cell culture of Caco-2 cells. Seeded in 3D Caco-2 cells start to differentiate already 
on the 2-cell stage (apical F-actin accumulation). After approximately 10 days of culture they 
form fully polarized cysts with a fluid filled lumen. The cysts show clear apical-basolateral 
differentiation by apical F-actin and basolateral E-cadherin accumulation (scale: 10µm). 
In recent years the development of more advanced 3D intestinal organoid cultures derived 
from primary tissues has enabled the study of differentiation programs and epithelial 
tissue organization in a colorectal cancer setting ex vivo in even more detail [45]. The 
intestinal organoids resemble the natural assembly of the intestinal epithelium including 
the crypt/villus structure and therefore the intestinal stem cell niche (Fig. I-5), enabling 
not only research on self-renewal processes but also the role of cancer stem cells in these 
organoid cultures [108]. The organoids can be isolated from genetically engineered mice, 
carrying the genotype of this mouse lineage or can be directly modified by transfection or 
precise genome editing methods. Thereby new model systems developed. Today human 
intestinal organoids from healthy donors can be precisely manipulated to resemble 
specific cancer genotypes [109]. Whole libraries of organoids from different tumor 
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subtypes are used to study tumorigenesis and drug sensitivity in the heterogeneous 
setting of CRC [110,111]. As this organoid culture technique is much more complex and 
requires still donor animals I used the 3D model of Caco-2 cells as a surrogate model in 
this study and organoid experiments were performed for validation by our partners [112]. 
5.3. Culture model for K-Ras mutated CRC 
To study the early stages of transformation of CRC from adenoma to carcinoma, the 
Caco-2 cells inducibly expressing oncogenic K-RasG12V were utilized [113]. The tetracycline 
(Tet)-inducible expression system (tetON system) enables the timely expression of the 
oncogene by addition of doxycycline (dox) to the cell culture. The bi-cistronic K-Ras-IRES-
GFP transcriptional cassette gets activated [114] leading to the acute expression of 
K-RasG12V and free GFP that can be easily detected by fluorescence microscopy and serves 
as a surrogate marker for oncogene expression.  
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I I .  M A T E R I A L  A N D  M E T H O D S
1. BUFFERS, SOLUTIONS AND REAGENTS
1.1. Protein extraction, SDS-PAGE and Western blotting 
Blocking solution: 0.5% (v/v) blocking solution (Roche Diagnostics, Basel, Switzerland), 
0.05% (v/v) Tween-20, 0.01% (v/v) thimerosal in PBS  
Blotting buffer: 200 mM glycine, 25 mM Tris base, 20% (v/v) methanol in ddH2O 
Laemmli protein sample buffer (5x): 400 mM Tris pH 6.8, 500 mM dithiothreitol, 50% 
(v/v) glycerol, 10% (w/v) SDS, 0.2% (w/v) bromophenol blue in ddH2O 
PBS: 140 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4 in ddH2O, pH 7.4 
PBS-Tween: 0.05% (v/v) Tween-20 in PBS 
RIPA buffer: 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton-X 100, 0.5 sodium 
deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM sodium fluoride and 
20 mM β-glycerophosphate plus Complete protease inhibitors in ddH2O (Roche) 
SDS-PAGE running buffer: 25 mM Tris pH 8.8, 192 mM glycine, 0.1% (v/v) SDS in ddH2O 
SDS-PAGE running gel solution: 8%/10%/12% (v/v) acrylamide, 375 mM Tris pH 8.8, 0.1% 
(w/v) SDS, 0.1% APS, 0.06% TEMED in ddH2O 
SDS-PAGE stacking solution: 5% (v/v) acrylamide, 130 mM Tris pH 6.8, 0.1% (w/v) SDS, 
0.1% APS, 0.1% TEMED in ddH2O 
1.2. Viability Assay 
MTT solution: 5 mg/ml 3-(4,5-dimethylthiazol-2yl-)2,5-diphenyl tetrazolium (MTT; Roth, 
Karlsruhe, Germany) in PBS 
MTT-Stop solution: 10% SDS in ddH2O, 50% N,N-Dimethylformamid 
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1.3. Immunofluorescence 
Blocking solution: 5% (v/v) goat serum (Invitrogen, Karlsruhe, Germany), 0.1% (v/v) 
Tween-20 
PFA fixing solution: 4% (v/v) PFA in PBS 
Permeabilizing solution: 0.2% (v/v) Triton X-100 in PBS 
Mounting solution: Fluoromount G (Southern Biotechnology, Birmingham, AL, USA) 
1.4. Kits 
Protein concentration: DC Protein Assay (Bio-Rad, Hercules, USA)  
Western Blot Detection: HRP SuperSignal®West substrate pico (Pierce/Thermo, 
Rockford, USA); HRP SuperSignal®West substrate dura (Pierce/Thermo) 
Cell Viability: CytoTox-Glo™ Cytotoxicity Assay (Promega, Madison, WI, USA); Caspase-
Glo®3/7 Assay (Promega); in situ cell death detection kit (TMR) (Roche) 
Western Blotting: NuPAGE® Novex Bis-Tris Gel; iBlot®Gel Transfer Stacks (both 
Invitrogen) 
RNA Isolation: RNeasy® Plus Mini Kit (Qiagen, Foster City, CA, USA) 
qPCR: QuantiTect Primer Assays® for SYBR® Green-based expression analysis (Qiagen) 
2. CELL CULTURING 
2.1. Cell lines 
Fresh cultures of the human cell lines were established every three months from frozen 
stocks stored in liquid nitrogen. Caco-2, HCT-116, and LoVo cells were obtained from 
Interlab Cell Line Collection (Genova, Italy) in 2012 and Caco-2 cells were reauthenticated 
by SNP analysis in 2016 (Multiplexion, Immenstadt, Germany). 
Caco-2tet cells, stably expressing the doxycycline-inducible system components rtTA and 
rtTS [113] and Caco-2tet B-RafV600E, Caco-2tet K-RasG12V and Caco-2tet vector cells were 
described previously [104,113]. The corresponding parental cells were authenticated in 
2014 (Multiplexion). All Caco-2tet cell lines were kindly provided by Prof. Tilman 
Brummer, University Freiburg. 
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2.2. Cell culture media and reagents 
Medium: RPMI 1640 (Invitrogen); DMEM (Invitrogen) 
Matrix: PureCol®-S collagen (Advanced Biomatrix, San Diego, CA, USA); Growth factor 
reduced matrigel (BD) 
Supplements: Fetal calf serum (FCS) (PAA Laboratories, Pasching, Austria); Choleratoxin 
(CTX; Sigma Aldrich); Doxycycline (dox; Merck, Darmstadt, Germany) 
Reagents: Trypsin/EDTA (10x) (Invitrogen); Cell Recovery Solution (BD) 
Growth factors: EGF (Sigma-Aldrich); TGF-α, HB-EGF, HRG (PeproTech, Hamburg, 
Germany); AREG, EREG, BTC (ImmunoTools, Friesoythe, Germany)  
Small molecules / Inhibitors: pan-ErbB inhibitor AZD8931 (Sapitinib) (Absource 
Diagnostics, Munich, Germany); Z-VAD-FMK (Bachem AG, Bubendorf, Switzerland); 
SM83 (synthesis and purification of was described previously [115,116]) 
Antibodies / Inhibitors: Cetuximab from Merck (Darmstadt, Germany); Db-scTRAIL (was 
produced in HEK293 cells and purified from cell culture supernatants [66]) 
3. ANTIBODIES AND FLUORESCENT DYES 
3.1. Immunoblotting 
All antibodies were diluted in blocking solution; for primary antibodies 0.01% (v/v) azide 
was added for storage at 4°C. 
List of primary and secondary antibodies with the used dilution for immunoblotting, 
sorted by name of antigen: 
primary antibodies 
monoclonal mouse anti-alpha-tubulin (1:5000) (Sigma-Aldrich, St Louis, MO, USA)  
monoclonal rabbit anti-pAKT (T308) (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal mouse anti-pAKT (S473) (1:1000) (Cell Signaling, Danvers, MA, USA)  
monoclonal mouse anti-AKT (pan) (1:1000) (Cell Signaling, Danvers, MA, USA)  
polyclonal rabbit anti-Bcl-2 (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal rabbit anti-Bcl-xL (1:400) (Cell Signaling, Danvers, MA, USA) 
monoclonal rabbit anti-caspase 3 (1:1000) (Cell Signaling, Danvers, MA, USA)  
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polyclonal rabbit anti-cIAP1 (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal rabbit anti-cIAP2 (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal rabbit anti-pEGFR/ErbB1 (Y1068) (1:1000) (Cell Signaling, MA, USA) 
monoclonal mouse anti-EGFR/ErbB1 (1:500) (Thermo Scientific, Fremont, MA, USA)  
monoclonal rabbit anti-pErbB2 (Y1221/1222) (1:500) (Cell Signaling, Danvers, MA, USA)  
polyclonal rabbit anti-ErbB2 (1:1000) (Santa Cruz Biotechnology, Dallas, TX, USA) 
monoclonal rabbit anti-pErbB3 (Y1289) (1:500) (Cell Signaling, Danvers, MA, USA)  
polyclonal rabbit anti-ErbB3 (1:1000) (Santa Cruz Biotechnology, Dallas, TX, USA)  
polyclonal rabbit anti-pERK (T202/Y204) (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal mouse anti-ERK (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal mouse anti-FlipS/L (1:400) (Santa Cruz Biotechnology, Dallas, TX, USA) 
monoclonal mouse anti-GFP (1:1000) (Roche Applied Science, Mannheim, Germany)  
monoclonal mouse anti-Ras (1:200) (BD, CA, San Jose, USA)  
monoclonal mouse anti-Smac (1:1000) (Cell Signaling, Danvers, MA, USA) 
monoclonal rabbit anti-survivin (1:1000) (Cell Signaling, Danvers, MA, USA) 
polyclonal rabbit anti-TRAILR1 (1:1000) (Santa Cruz Biotechnology, Dallas, TX, USA) 
polyclonal rabbit anti-TRAILR2 (1:500) (Cell Signaling, Danvers, MA, USA) 
monoclonal mouse anti-xIAP (1:400) (BD, CA, San Jose, USA) 
secondary antibodies 
HRP-labeled secondary anti-mouse and anti-rabbit IgG antibodies (1:10000) were from 
GE Healthcare (Buckinghamshire, UK).  
3.2. Immunofluorescence staining 
All antibodies were diluted freshly in blocking buffer. 
List of primary and secondary antibodies and fluorescent dyes that were used for 
immunofluorescence with corresponding dilution, sorted by name of antigen: 
primary antibodies 
polyclonal rabbit anti-aPKC (zeta) (1:200) (Santa Cruz Biotechnology, Dallas, TX, USA) 
monoclonal mouse anti-E-cadherin (1:250) (BD, CA, SanJose, USA)  
polyclonal rabbit anti-ZO-1 (1:200) (Invitrogen)  
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secondary antibodies 
Alexa Fluor 488- and 546- labeled secondary anti-mouse and anti-rabbit IgG antibodies 
(1:500) and Alexa Fluor 633-labeled phalloidin (1:100) (Invitrogen) were used.  
fluorescence dyes 
nuclear staining: DAPI (1:1000) (Sigma-Aldrich, St. Louis, USA)  
F-actin staining: Alexa Fluor® 633 phalloidin (1:100) (Invitrogen) 
4. SMALL INTERFERING RNA (SIRNAS) 
All siRNAs were diluted in 1x siRNA buffer (MWG Biotech) to a final concentration of 
20 µM. As non-targeting negative controls (siNT) ON-TARGETplus® non-targeting control 
pool (Dharmacon) or Silencer®Select Negative Control#2 (Invitrogen) were used. In all 
cases, two independent siRNAs were used: siErbB1 refers to siGenome SMARTpool EGFR 
(M-003114-03-0005) from Dharmacon; siErbB1#2 refers to Silencer®Select ErbB1 (s565) 
(Invitrogen); siErbB2 refers to a single duplex with the sense sequence: 5´- 
GGACGAAUUCUGCACAAUG-3´, from Eurofins MWG Operon; siErbB2#2 refers to 
Silencer®Select ErbB2 (s612) from Invitrogen; siErbB3 refers to siGenome SMARTpool 
ErbB3 (M-003127-03-0005) from Dharmacon; siErbB3#2 refers to Silencer®Select ErbB3 
(s4779) from Invitrogen); siHRG1#1 refers to Silencer®Select NRG1 (s230508), siHRG1#2 
refers to Silencer®Select NRG1 (s230507), siHRG2#1 refers to Silencer®Select NRG2 
(s18322) and siHRG2#2 refers to Silencer®Select NRG2 (s18321) (all from Invitrogen).  
5. METHODS 
5.1. Cell culturing 
Caco-2, HCT-116, and LoVo cell lines were cultured in RPMI 1640 and Caco-2tet cells in 
DMEM, both supplemented with 10% FCS without antibiotics. Cell lines were incubated in 
a humidified atmosphere of 5% CO2 at 37 °C. When cells reached 70-80% confluence, they 
were transferred to a new cell culture vessel; detachment was achieved by using 1x 
trypsin/EDTA. For growth factor dependent assays cells were grown in medium containing 
2% FCS plus 10 ng/ml growth factor.  
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3D cell culture  
For growth in 3D, cells were seeded on a bed of growth factor reduced matrigel and 
PureCol®-S collagen (1:1) and overlaid with growth medium containing 2% matrigel. 
Lumen expansion was induced by addition of 100 ng/ml Choleratoxin (CTX) at day 3 post 
seeding. Transgene expression in the Caco-2tet cells was induced by 2 µg/ml doxycycline 
(dox). 
Transient transfection with siRNAs 
Cells were transiently transfected with siRNA using DharmaFECT1 (Dharmacon, Lafayette, 
CO, USA) according to manufacturer's instructions. For transient transfections of Caco-2 or 
Caco-2tet cells 1.8*105 cells/well in 1 ml medium were seeded in 12-well dishes. The next 
day medium was exchanged with 800 µl fresh growth medium and 200 µl transfection mix 
was added, prepared according to manufacturer’s protocol. One day later cells were 
replated for further experiments. All steps described were performed with RNase-free 
solutions, reaction tubes and pipette tips to avoid RNAse contamination. 
5.2. MTT, cytotoxicity, and caspase 3/7 activity assays  
For 2D cultures, 2.5*103 cells/well in 100 µl medium were plated into uncoated 96-well 
plates. For 3D cultures, 5*103 cells/well were seeded into matrigel/collagen-coated 96-
well plates in 100 µl medium containing 2% matrigel. Viability was determined by addition 
of 10 μl MTT solution (5 mg/ml) followed by incubation for 3 h. Cells were lysed by 
addition of 100 μl MTT-stop solution and absorbance was measured at 570 nm using the 
multimode reader Infinite® 200 PRO (Fa. Tecan, Männedorf, Switzerland). Cytotoxicity was 
measured using the CytoTox-Glo™ Cytotoxicity Assay (Promega). The activity of dead-cell 
protease in the culture was determined by addition of 50 µl luminogenic substrate. After 
15 min incubation at RT, luminescence was measured using the multimode reader 
Infinite® 200 PRO (Fa. Tecan), followed by cell lysis and measurement of total 
luminescence for normalization. Caspase 3/7 activity was determined using the Caspase-
Glo®3/7 Assay (Promega) by addition of 70 µl luminogenic substrate containing the DEVD 
sequence. After 30 min incubation at RT, luminescence was measured using the 
multimode reader Infinite® 200 PRO (Fa. Tecan). 
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5.3. Immunofluorescence microscopy 
Cells grown in 3D on matrigel/collagen coated 8-well glass chamber slides (BD) were fixed 
with 4% PFA for 15 min, permeabilized 10 min and blocked with 5% goat serum in PBS-
Tween. Cells were then incubated with primary antibodies in blocking buffer (2 h at RT), 
washed with PBS-Tween and incubated with secondary antibody in blocking buffer (2 h at 
RT). F-actin and nuclei were counterstained with Alexa Fluor 633-labeled phalloidin and 
DAPI. Slides were mounted in Fluoromount G and analyzed on a confocal laser scanning 
microscope. To determine the number of polarized cysts with a ‘predominant single apical 
lumen’ (PSAL) [42], spheroids were analyzed in terms of roundness, cell-free lumen 
formation and F-actin staining of the apical surface. Round spheroids with a single-cell 
layer around a hollow lumen and distinct F-actin staining were scored as 
normal/polarized, cysts lacking at least two of these features were scored as 
abnormal/unpolarized.  
5.4. Tunel staining 
DNA strand breaks were analyzed with the in situ cell death detection kit (TMR red; 
Roche). Cells grown in 3D culture were fixed with 4% PFA for 1 h at RT and permeabilized 
with 0.1% Triton-X 100 in 0.1% sodium citrate for 2 min at RT. Labeling was performed 
according to the manufacturer’s protocol for 1 h at 37°C. Nuclei were counterstained with 
DAPI. Slides were mounted in Fluoromount G and analyzed on a confocal laser scanning 
microscope (LSM 700; Zeiss, Oberkochen, Germany). Images were processed with the ZEN 
software (Zeiss). Tunel-positive cells were counted using ImageJ (W Rasband, National 
Institute of Health, USA; V 1.48). 
5.5. Western blotting  
Cells were lysed in RIPA buffer. For lysates from 3D cultures, cells were cultured on pure 
matrigel without collagen. Spheroids were isolated after 4 days by dissolving the matrigel 
in ice cold Cell Recovery Solution (BD). After centrifugation for 4 min at 200*g and 4 °C, 
supernatant was discharged and the remaining spheroids were lysed in RIPA buffer. 
Lysates were clarified by centrifugation for 10 min at 13,000 rpm and 4°C. Supernatant 
was transferred to a new tube and either directly separated by SDS polyacrylamide gel 
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electrophoresis (SDS-PAGE) or stored at -20 °C. To determine total protein concentration, 
the DC Protein Assay was utilized according to the manufacturer´s instructions. Proteins 
were denaturated in 1x Laemmli sample buffer for 5 min at 100 °C. Equal amounts of 
protein were separated by SDS-PAGE (NuPAGE® Novex Bis-Tris Gel; Invitrogen) and 
transferred to nitrocellulose membrane (iBlot®Gel Transfer Stacks; Invitrogen). 
Alternatively lysates were loaded on 8%/10%/12% polyacrylamide gels, depending on the 
molecular weight of the analyzed proteins, and transferred to polyvinylidene difluoride 
membranes (Roth). Membranes were blocked with 0.5% blocking reagent (Roche) and 
incubated with primary antibodies, followed by HRP-conjugated secondary antibodies. 
Visualization was done with ECL detection system (Pierce).  
5.6. FACS analysis 
Analysis of transgene expression of the Caco-2tet cells was performed after 72 h dox 
treatment. Cells were detached with Trypsin, washed, re-suspended in PBS containing 2% 
FCS and 0.01% sodium azide, and analyzed using an EPICS FC500 flow cytometer (Beckman 
Coulter, Krefeld, Germany). Post-acquisition data analysis was performed using FlowJo 
software (Tree Star; Ashland, OR, USA). 
5.7. Quantitative PCR  
Total RNA was isolated from cells using the RNeasy® Plus Mini Kit (Qiagen) according to 
the manufacturer’s protocol. For 2D cell cultures, 2*105 to 1*106 cells were lysed with RLT 
buffer. For 3D culture, 4*105 cells were seeded in 12-well plates on matrigel, as described 
for protein extraction. Pelleted spheroids were lysed in 350 µl RLT buffer. RNA samples 
were quantified using a Nanophotometer (Implen, Munich, Germany) at OD 260/280 nm. 
q-PCR was performed with QuantiTect Primer Assays® for SYBR® Green-based expression 
analysis (Qiagen) using a Cfx96 device (Biorad) according to the manufacture’s protocol for 
one-step RT-PCR. Changes in the relative expression level were calculated using the 2-
ΔΔCt method (CFX manager software 3.1, Biorad). GAPDH was used as the endogenous 
control gene for normalization. Used primers were Hs_NRG1_1_SG QuantiTect Primer 
Assay, Hs_NRG2_1_SG QuantiTect Primer Assay and Hs_GAPDH_2_SG QuantiTect Primer 
Assay (all Qiagen). 
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5.8. Statistical analysis 
Data are expressed as mean ± S.E.M.; ‘n’ refers to the number of samples/experiment, ‘N’ 
to the number of independent experiments. Statistical significance was evaluated by t-test 
and one-way ANOVA followed by Tukey’s post-test (GraphPad Prism version 4.03; 
GraphPad Software Inc., La Jolla, CA, USA). p-values below 0.05 were considered as 
significant (*p < 0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05). 
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I I I .  R E S U L T S
1. ONCOGENIC RAS AND ERBB3 SIGNALING
 - IN HYPERPROLIFERATION AND POLARIZATION DEFECTS-  
The human CRC cell line Caco-2 forms polarized cysts when grown in 3D matrigel cultures, 
recapitulating morphological features of the intestinal epithelium. These cysts are 
characterized by a single epithelial cell layer with apical-basolateral polarity that 
surrounds a hollow lumen [107]. In this study I used parental Caco-2 cells and a Caco-2tet 
cell line that inducibly express oncogenic K-RasG12V. Thus this cell lines are well suited to 
investigate the influence of acute expression of oncogenic Ras on proliferation and 
differentiation in the context of CRC.  
K-RasG12V expression impede Caco-2 polarization in 3D 
In the Cao-2tet K-RasG12V cells addition of doxycycline induces the bi-cistronic expression 
of the oncogene K-RasG12V and GFP, whereas vector control cells express GFP only. Three 
days after dox addition, more than 85% of the cells were GFP positive by FACS analysis 
(Fig. III-1a). Immunoblotting of Caco-2tet K-RasG12V cell lysates confirmed Ras 
overexpression along with that of GFP, concomitant with strong ERK phosphorylation, 
whereas vector control cells expressed only GFP (Fig. III-1b).  
When these cells were seeded into 3D cultures in the absence of doxycycline, both 
Caco-2tet vector and K-RasG12V cells formed well-differentiated and polarized spheroids 
with basolateral adherens junctions (E-cadherin staining) and apical F-actin accumulation 
around a cell-free lumen. Addition of doxycycline had no effect on the morphology of the 
control cells, expressing GFP only, whereas the K-RasG12V expressing cells formed multi-
luminal spheroids that lacked distinct polarization (Fig. III-2). These differentiation defects 
caused by K-RasG12V are in accordance with a recent report by Magudia et al. [88].  
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Figure III-1: Inducible expression of oncogenic K-Ras
G12V
 in Caco-2tet cells. (a) Caco-2tet vector 
control and K-Ras
G12V
 cells were treated with 2 µg/ml dox for 72 h (+ dox). Cells were harvested 
and GFP fluorescence was analyzed by flow cytometry. Non-induced cells were used as a control 
(- dox). (b) Caco-2tet vector control and K-Ras
G12V
 cells were grown in 2D treated with dox for the 
indicated times prior to lysis. Lysates were analyzed by immunoblotting using the indicated 
antibodies. Tubulin was detected as loading control. All panels shown are from the same blot.  
 
Figure III-2: Expression of oncogenic K-Ras
G12V
 in Caco-2tet cells interferes with normal 
morphogenesis. Caco-2tet vector control and K-Ras
G12V
 cells were seeded into 3D cultures in the 
absence or presence of dox. Three days post seeding lumen expansion was induced by addition 
of CTX. Cultures were fixed three days later and stained with E-cadherin-specific antibody 
(green), phalloidin (F-actin; red) and DAPI (nuclei; blue). Shown are confocal sections of 
representative cysts (scale: 10 µm). 
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Quantification of the effects of K-RasG12V expression, visualized by the bi-cistronic GFP 
expression, showed that the average number of cells in the midplane of the cysts doubled 
compared to the non-induced control and only 15% of the cysts were scored as normally 
differentiated, based on morphological criteria (see methods for details) including well-
defined apical F-actin accumulation (Fig. III-3a-c).  
 
Figure III-3: Quantification of aberrant morphogenesis of Caco-2tet K-Ras
G12V
 cells in 3D culture. 
(a) Caco-2tet K-Ras
G12V
 cells were seeded into 3D in the absence or presence of dox. Three days 
post seeding lumen expansion was induced by addition of CTX. Cultures were fixed two days later 
and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red). GFP is co-expressed with 
K-Ras
G12V
 (green). Shown are confocal sections of the midplane of representative cysts, nuclei are 
numbered in white (scale: 20 µm). (b) The percentage of differentiated cysts from (a) was 
determined (n>70; N=3). (c) The number of nuclei in the midplane of cysts was counted as 
depicted in (a) (n=25; N=3).  
ErbB receptor inhibition restores Caco-2tet K-RasG12V polarization 
To investigate the potential contribution of the ErbB receptors to the aberrant 
morphogenesis and hyperproliferation induced by K-RasG12V expression, the doxycycline-
containing 3D cultures were treated with the pan-ErbB inhibitor AZD8931. 
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Interestingly, the abnormal morphology of K-RasG12V-expressing Caco-2 cysts was partially 
restored, with almost 40% of cysts displaying polarized structures with a predominant 
single apical lumen (Fig. III-4a,b) and a significant reduction of cyst size (Fig. III-4c), 
comparable to that of K-RasG12V cells without dox (Fig. III-3c).  
 
Figure III-4: ErbB receptor inhibition restores morphogenesis of Caco-2tet K-Ras
G12V
 cells in 3D. 
(a) Caco-2tet K-Ras
G12V
 cells were seeded into 3D cultures. One day post seeding K-Ras
G12V
 
expression was induced with dox and cultures were left untreated (ut) or treated with 200 nM 
AZD8931. Two days later CTX was added to the culture. Cultures were fixed the next day and 
stained with DAPI (nuclei; blue), anti-aPKC antibody (cyan) and phalloidin (F-actin; red). GFP is co-
expressed with K-Ras
G12V
 (green). Shown are confocal sections of the midplane of representative 
cysts (scale: 20 µm). (b) The percentage of differentiated cysts of (a) was determined (n>60; 
N=3). (c) The number of nuclei in the midplane of cysts of (a) was counted (n=25; N=3). 
Analysis of inhibitor treatment affecting ErbB receptor signaling showed low basal 
phosphorylation of AKT and ERK in the non-induced cells (-dox). K-RasG12V expression 
(+dox) revealed hyperactivation of MAPK and PI3K pathways. ErbB1 phosphorylation was 
readily detectable in both control and K-RasG12V-expressing cells, whereas no 
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phosphorylation was visible for ErbB2 and ErbB3. Expression of ErbB4 was below the 
detection limit in this cell line (data shown in [112]).  
AZD8931 potently suppressed ErbB1 phosphorylation in control (-dox) and oncogenic Ras-
expressing cells. Comparable results were obtained with a second inhibitor (ErbB2-II), 
which also restored the morphogenetic defects in Caco-2tet RasG12V cells. This inhibitor 
blocked HRG-induced ErbB2 and ErbB3 activation, but had no effect on EGF-induced ErbB1 
phosphorylation (data shown in [112]).  
ErbB3 is required for the K-RasG12V induced polarization defect 
To identify the ErbB receptors that cooperate with K-RasG12V signaling, gene silencing 
experiments were performed. Caco-2tet K-RasG12V cells were transfected with control 
siRNA (siNT) or ErbB receptor-specific siRNAs (siErbB1/2/3) and then seeded into 3D 
culture, followed by the induction of K-RasG12V expression the next day.  
Morphological analysis revealed that the cysts formed by oncogenic Ras-expressing cells 
depleted of ErbB1 or ErbB2 were comparable to those transfected with the siRNA control. 
By contrast, upon ErbB3 depletion, the K-RasG12V-induced defect in polarized 
morphogenesis was rescued, as seen by the apical accumulation of the apical markers 
atypical PKC (aPKC) and F-actin (Fig. III-5a,b). Note that K-RasG12V expression was not 
affected by the siRNA transfection as judged by the GFP signal. Additionally, in the 
absence of ErbB3, the hyperproliferation triggered by K-RasG12V was abrogated (Fig. III-5c) 
with average cell numbers in the midplane of cysts comparable to those observed in non-
induced control cultures (see Fig. III-3c). This was specific to the 3D cultures, as ErbB3 
depletion did not affect the proliferation of RasG12V-expressing cells grown in 2D 
monolayers (data not shown). ErbB receptor knockdown was verified by immunoblotting 
(Fig. III-5d) and similar results were obtained by independent siRNAs (data not shown).  
Taken together, these findings uncover a role for ErbB3 signaling in oncogenic Ras-induced 
hyperproliferation and polarity loss, which were partially rescued by pharmacologic pan-
ErbB inhibition or specific siRNA-mediated knockdown. 
 III. RESULTS 
 
38 
 
 
Figure III-5: ErbB3 knockdown rescues hyperproliferation and polarized morphogenesis of 
Caco-2 cells expressing oncogenic K-Ras. (a) Caco-2tet K-Ras
G12V
 cells were transfected with non-
targeting (siNT) and ErbB receptor-specific siRNAs, respectively. The next day cells were seeded 
into 3D. One day post seeding K-Ras
G12V 
expression was induced with dox. Two days later CTX was 
added. Cultures were fixed the next day and stained with DAPI (nuclei; blue), anti-aPKC antibody 
(cyan) and phalloidin (F-actin; red). GFP is co-expressed with K-Ras
G12V
 (green). Shown are 
confocal sections of the midplane of representative cysts (scale: 20 µm). (b) The percentage of 
differentiated cysts of (a) was determined (n>70; N=3). (c) The number of nuclei in the midplane 
of cysts of (a) was counted (n=25; N=3). (d) Two days after gene silencing, lysates were generated 
and analyzed by immunoblotting using the indicated antibodies. Tubulin was detected as a 
loading control. Specific bands are marked by arrowheads. 
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ErbB3 activation by HRG disrupts Caco-2 cyst formation 
To analyze the impact of specific activation of the different ErbB receptors by their ligands 
concerning Caco-2 3D proliferation and morphogenesis, parental cells were seeded in 
growth factor-reduced matrigel with low serum (2%) in the presence of the different ErbB 
ligands. Stimulating effects on proliferation were detected following EGF, TGF-α, and 
HB-EGF addition and strongest stimulation was induced by HRG (Fig. III-6a).  
 
Figure III-6: Heregulin induces hyperproliferation and impairs polarized morphogenesis of 
Caco-2 cysts. (a) Caco-2 cells were grown in 3D containing 2% FCS in the presence of the 
indicated growth factors (10 ng/ml) or in 2% FCS only as a control (con). Cultures were analyzed 
by MTT assay at day 6 (N=3). (b,c) Cells were grown as described in (a). Three days after seeding 
CTX was added. Cultures were fixed the next day and stained with DAPI (nuclei; blue) and 
phalloidin (F-actin; red). (b) The percentage of differentiated cysts was determined (n>70; N=3). 
(c) Shown are confocal sections of the midplane of representative cysts (scale: 20 µm).  
Importantly, despite effects on proliferation as seen by the increased sizes of cysts 
(Fig. III-6c), apart from HRG, none of the ErbB ligands interfered with polarized cyst 
morphology and lumenogenesis (Fig. III-6b). In the presence of HRG, a significant drop in 
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the percentage of polarized cysts was noted (Fig. III-6b,c), similar to the phenotype 
induced by K-RasG12V. Expression of aPKC and E-cadherin, which demarcate the apical and 
basolateral membranes, respectively, were retained in the presence of HRG, but aPKC was 
mislocalized (Fig. III-7a). To prove that HRG signaling was disrupting apical-basolateral 
polarity and not simply inducing hyperproliferation leading to luminal filling, cyst 
development was analyzed in more detail. Already at the two-cell stage, apical-basolateral 
polarization is observed, with F-actin accumulating at the cell-cell interface, associated 
with the formation of tight junctions that are positive for ZO-1 (Fig. III-7b; day 2, -HRG). 
This apical surface is maintained as the cyst develops, specifying the position of the lumen. 
HRG interfered with correct F-actin localization and ZO-1 recruitment, indicating that the 
initial establishment of polarity and tight junctions were impaired (Fig. III-7b,c). 
 
Figure III-7: Heregulin impairs apical-basolateral polarity and lumenogenesis of Caco-2 3D 
cultures. Caco-2 cells were grown in 3D containing 10% FCS in the presence or absence of HRG 
(10 ng/ml) (a) Cells were fixed at day 5 one day after addition of CTX and stained with anti-E-
cadherin antibody (green), anti-aPKC antibody (cyan) and DAPI (nuclei; blue). (b,c) Cultures were 
fixed at the indicated days after seeding, and stained with DAPI and phalloidin (F-actin; red). At 
day three CTX was added. (b) Shown are confocal sections of the midplane of representative 
cysts (scale: 20 µm). (c) The percentage of differentiated cysts was determined (n>25; N=2).  
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To address the qualitative differences in receptor activation and downstream signaling 
Caco-2 2D monolayers were stimulated for 15 min with the different ErbB ligands. 
Phosphorylation levels of ErbB1, ERK and AKT induced by EGF, TGF-α and HB-EGF closely 
mirrored the growth stimulation observed. HRG is the only exception. It stimulated ErbB3 
phosphorylation associated with strong PI3K pathway activation, as judged by AKT 
phosphorylation (Fig. III-8a). ErbB2 phosphorylation at Tyrosine 1222/1221 was barely 
detectable following application of any ligand. Phosphorylation after EGF, TGF-α and 
HB-EGF and HRG stimulation was observed at Tyrosine 1248 only (data not shown).  
 
Figure III-8: HRG activates ErbB3 signaling and PI3K pathway. (a) Caco-2 cells were seeded in 2D, 
serum-starved overnight (2% FCS) and, prior to lysis, stimulated with the indicated growth factors 
(10 ng/ml) for 15 min or left untreated (con). Lysates were analyzed by immunoblotting. Tubulin 
as a loading control was detected. Shown is a representative blot (N=2). (b) Caco-2 cells grown in 
3D containing 2% FCS in the presence of the indicated growth factors (10 ng/ml) or in 2% FCS 
(con). Three days post seeding cysts were lysed and analyzed by immunoblotting using the 
indicated antibodies (pErbB2(Tyr1248)). Tubulin was detected as loading control. Shown is a 
representative blot (N=2) [experiment (b) performed by S. Schmid [112]]. 
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A comparison of the activation of the signaling molecules after incubation of 3D cultures 
for four days, focusing on EGF or HRG showed that ErbB receptor phosphorylation was still 
enhanced compared to the 2% serum control, but ERK phosphorylation was 
downregulated after prolonged ligand stimulation, whereas Stat3 phosphorylation was 
slightly elevated in the presence of the ligands. Compared to EGF, HRG led to sustained 
AKT phosphorylation in this experiments (3-fold) at serine 473 (Fig. III-8b), which was 
comparable to the extent of AKT phosphorylation induced by K-RasG12V. Long-term 
stimulation with EGF or HRG suppressed ERK activation, probably owing to compensatory 
feedback mechanisms. Finally, to prove that ErbB3 was mediating the HRG effect, 
knockdown of ErbB3 and also ErbB2, as ErbB3 preferentially heterodimerizes with ErbB2, 
was performed. In the absence of HRG, the receptor knockdowns had little effect on the 
polarized morphogenesis of the control cultures (siNT) (Fig. III-9a, left). However, in the 
presence of HRG, ErbB3 depletion fully restored polarized cyst structure and lumen 
formation to the level seen in the control. Knockdown of ErbB2, however, failed to do so 
(Fig. III-9a, right). Knockdown efficiency was comparable for both receptors (Fig. III-9b). 
 
Figure III-9: HRG-induced ErbB3 signaling impairs polarized morphogenesis of Caco-2 cells. (a) 
Caco-2 cells were transfected with non-targeting (siNT) and ErbB-receptor specific siRNAs, 
respectively. The next day, cells were seeded into 3D in the presence or absence of HRG 
(10 ng/ml). Three days post seeding lumen expansion was induced by addition of CTX.. The 
percentage of differentiated cysts was determined (n>50; N=3). (b) Two days after gene silencing, 
lysates were generated and analyzed by immunoblotting. Tubulin was detected as a loading 
control. Specific bands are marked by arrowheads. 
Experiments in 3D murine intestinal organoid cultures, as an organotypic model for 
normal intestinal epithelium, confirmed the morphological phenotypes found after EGF 
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and HRG stimulation [112]. Here the outgrowth of single intestinal crypts into organoids 
with a crypt-villus axis was stalled in the absence of ErbB1 ligands. EGF supported the 
outgrowth of organoids, as reported previously [45]. However the substitution of EGF by 
HRG lead to hyperproliferative organoids with multiple irregularly shaped crypts and 
mislocalized F-actin.  
Taken together, the analysis of normal tissue is consistent with the here described data 
obtained from Caco-2 cells and provides support that activation of a HRG-ErbB3-AKT 
signaling axis can contribute to hyperproliferation and tissue disorganization in the 
intestinal epithelium. 
K-RasG12V induced HRG2 expression is responsible for the observed polarization defect 
Based on these findings, I hypothesized that K-RasG12V expression in Caco-2 3D cultures 
may lead to enhanced HRG production. Indeed, real-time qPCR analysis revealed that 
oncogene expression induced HRG1/2 transcript levels, which was significant for HRG2 in 
2D and 3D cultures (Fig. III-10a,b).  
It is particularly noteworthy that only active K-RasG12V but not active B-RafV600E led to HRG 
expression (Fig. III-10a), indicating that oncogenic K-Ras triggers a distinct transcriptional 
program. Comparison of human CRC cell lines with wild-type K-Ras genes and those 
carrying an active Ras-mutation revealed strongly increased HRG2 transcript levels in 
three out of four cases as well (SW480, LoVo, HCT116; Fig. III-10c). This indicates that the 
upregulation of HRG expression by oncogenic Ras signaling is not restricted to the Caco-2 
model system.  
Next, silencing of HRG expression prior to the induction of oncogenic Ras was performed. 
In full support of my hypothesis, the combined depletion of HRG1 and HRG2 reduced 
spheroid size and significantly increased the number of polarized cysts with apical lumen 
(Fig. III-11a-c). This rescue was also observed by independent siRNAs (Fig. III-11; #2) and 
was comparable to the rescue obtained by pharmacological ErbB inhibition (Fig. III-4b) or 
ErbB3 silencing (Fig. III-9a). HRG1/2 knockdown was confirmed by qPCR analysis 
(Fig. III-11c).  
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Figure III-10: Oncogenic K-Ras but not B-Raf induces HRG Expression. (a) Caco-2tet vector, B-Raf 
V600E
 and K-Ras
G12V
 cells were seeded into 2D in the presence of dox for 72 h. RNA was isolated 
and analyzed by qPCR for the expression of HRG1 or HRG2, normalized to GAPDH expression 
(N=3). (b) Caco-2tet K-Ras
G12V
 cells were seeded into 3D in the presence of dox for 72 h. Cysts 
were isolated and lysed. RNA was analyzed by qPCR for the expression of HRG1 or HRG2, 
normalized to GAPDH expression (N=3). (c) The indicated human CRC cell lines were seeded into 
3D culture. Three days later, cysts were isolated, RNA was extracted and HRG1 or HRG2 
expression was determined by qPCR, normalized to GAPDH (N=2) [experiment (c) performed by J. 
Hendrick [112]] 
To prove that HRG was acting through extracellular ErbB3 binding, treatment of the 
K-RasG12V expressing cells with an ErbB3-specific antibody that competes with HRG was 
performed (Fig. III-12a,b). Importantly, this treatment suppressed proliferation and 
significantly restored the number of cysts with a normal polarized morphology. In 
conclusion, the hyperproliferation and polarity loss induced by K-RasG12V expression in the 
3D Caco-2 model can be ascribed to autocrine HRG-ErbB3 signaling. Interestingly, it was 
shown that several ErbB ligands including HRG1 were upregulated in mouse adenoma 
compared to normal intestinal tissue [112], pointing at the existence of additional 
mechanisms activating ErbB receptor signaling during tumor initiation and progression. 
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Figure III-11: HRG depletion restores lumen formation in oncogenic K-Ras
G12V
 expressing Caco-2 
cells. (a) Caco-2tet K-Ras
G12V
 cells were transfected with non-targeting (siNT) and a mix of HRG1- 
and HRG2-specific siRNAs, respectively. Two independent siRNA sets were used (#1 and #2). The 
next day cells were seeded into 3D and K-Ras
G12V
 expression was induced with dox one day later. 
Two days later CTX was added. Cultures were fixed the next day and stained with DAPI (nuclei; 
blue), anti-aPKC antibody (cyan) and phalloidin (F-actin; red). GFP is co-expressed with K-Ras
G12V
 
(green). Shown are confocal sections of the midplane of representative cysts (scale: 20 µm). (b) 
The percentage of differentiated cysts of (a) was determined (n>70; N=3). (c) Two days after gene 
silencing (independent siRNA sets #1 and #2) RNA of the transfected cells was extracted. HRG 
levels were determined by qPCR, normalized to GAPDH (N=3). 
Together with the increased ErbB3 positivity, detected in human high-grade primary CRC 
specimens [112], my findings provide support for an autocrine signaling loop engaged by 
oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal 
epithelium during tumor initiation and progression.  
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Figure III-12: ErbB3 specific inhibition by an antibody overcomes Ras
G12V
 induced polarization 
defects. (a) Cells were seeded into 3D culture in the presence of dox and were treated with 
100 nM anti-E3-IgG or left untreated (ut). Three days later CTX was added. Cultures were fixed 
the next day and stained with DAPI (nuclei; blue), anti-aPKC antibody (cyan) and phalloidin (F-
actin; red). GFP is coexpressed with K-Ras
G12V
 (green). Shown are confocal sections of the 
midplane of representative cysts (scale: 20 µm). (b) The percentage of differentiated cysts of (a) 
was determined (n>70; N=3). [experiment (a) performed by L. Schmitt and J. Hendrick [112]] 
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2. ONCOGENIC RAS AND ERBB1-TARGETED TRAIL
 - OVERCOMING APOPTOSIS RESITANCE BY A SMAC 
MIMETIC -  
Targeting of ErbB1 has become standard therapy in advanced CRC. Cetuximab, a 
monoclonal antibody against the extracellular domain of the ErbB1 receptor, interferes 
with ligand binding and thus activation of the receptor [117]. Retrospective analysis 
showed that ErbB1 targeting antibodies are only efficient in K-Ras wild-type tumors. Thus, 
the use of cetuximab was limited to K-Ras wild-type, ErbB1-expressing metastatic CRC in 
the year 2012 by the FDA. This restricts the application of the antibody dramatically, 
because one third of CRC patients harbor an activating mutation of Ras [75]. However, 
Ras/Raf mutated tumors often express high levels of ErbB1 and so the receptor could be 
used for the targeting of cytotoxic agents that for example induce apoptosis, 
independently of the mutational status of downstream signaling molecules. Here a single-
chain TRAIL molecule, fused to an diabody that contains the antigen-binding domains of 
cetuximab, was used to target the apoptosis inducing moiety to ErbB1-positive cells (Db-
scTRAIL, see Fig. I-9). This format previously showed efficient induction of apoptosis due 
to its hexameric configuration [66]. Furthermore Db-scTRAIL competes with ErbB1 ligand 
binding and receptor activation. To analyze the contribution of ErbB1 targeting to the Db-
scTRAIL-induced apoptosis in the setting of Ras wild-type and Ras mutant CRC cells I 
applied the Caco-2tet K-RasG12V model system. The parental cell line Caco-2 is ErbB1-
positive and therefore represents an ideal model system for studying the combined effect 
of ErbB1 inhibition and apoptosis induction in the context of oncogenic Ras. In addition to 
the effects induced by RasG12V expression, the contribution of cell culture conditions and 
ECM interaction to Db-scTRAIL sensitivity was investigated in the following part of my 
thesis. 
Cetuximab efficiently blocks ligand induced ErbB1 activation 
As shown in the previous experiments the different ErbB ligands differ in their capacity to 
drive the proliferation of Caco-2 cells (Fig. III-6). Firstly the presence of the most potent 
ErbB1 ligands, EGF and TGF- and how these ligands affected ErbB1 inhibition by 
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cetuximab was investigated. Cells were seeded in matrigel cultures containing low serum 
(2%) in the presence of EGF or TGF-α, ensuring that proliferation was mainly driven via 
ErbB1 signaling. MTT activity measurements after six days of cultivation indicated that EGF 
and TGF-α enhanced the proliferation of Caco-2 cells compared with control cells grown in 
low serum only (Fig. III-13a). Microscopic analysis revealed that in the presence of EGF and 
TGF-α Caco-2 cysts were larger and contained more cells (Fig. III-13b). In agreement with 
the previous results, the ErbB1 ligands did not interfere with polarized morphogenesis, as 
judged by the typical apical distribution of F-actin and the formation of a cell-free lumen 
(Fig. III-13b and III-6c).  
 
Figure III-13: Caco-2 3D cultures are sensitive to pharmacological ErbB1 inhibition. Caco-2 cells 
were grown in 3D culture containing 2% FCS in the presence of growth factors (10 ng/ml) or in 
2% FCS only (con). (a) Cultures were analyzed by MTT assay at day 6 and normalized to the 
control (N=5). (b) Caco-2 3D cultures were left untreated or treated with 0.5 µM cetuximab for 
72 h and analyzed by phase microscopy (scale: 50 µm). (c,d) Three days post seeding, 3D cultures 
were left untreated or treated with 0.5 µM cetuximab (cet) for 72 h. (c) Viability was determined 
by MTT assay and normalized to the untreated control (ut) (N=4). (d) Cytotoxicity was 
determined using the CytoTox-Glo Cytotoxicity Assay (N=3).  
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To address how ErbB1 blockade affected basal and ErbB1 ligand-induced proliferation of 
established Caco-2 cysts the cells were treated three days after seeding with cetuximab 
(0.5 µM) and analyzed three days later. Compared with the control, in these cultures the 
MTT activity was significantly reduced by 35-50%, but cells were still viable, did not show 
any signs of apoptosis and only negligibly increased cytotoxicity (Fig. III-13c,d).  
This indicates that ErbB1 activation contributes to basal proliferation, but is not required 
for survival. Cetuximab also potently inhibited proliferation in the presence of EGF and 
TGF-α as seen by the reduction of MTT activity and the reduced size of the cysts 
(Fig. III-13b,c). Together these experiments demonstrate that proliferation of Caco-2 cells 
in 3D cultures is sensitive to pharmacological ErbB1 inhibition and can thus potentially be 
suppressed by targeted compounds as Db-scTRAIL. 
3D culturing renders Caco-2 cells sensitive to Db-scTRAIL induced apoptosis 
To first test the efficacy of the targeting agent Db-scTRAIL, Caco-2 cells were cultured for 
three days in 3D in medium containing 10% FCS before addition of Db-scTRAIL followed by 
MTT measurements three days later. In these cultures, relatively low doses of Db-scTRAIL 
caused a significant reduction of cell viability which was associated with the disruption of 
cysts and the formation of apoptotic bodies (Fig. III-14a,b) and induction of apoptosis 
(Fig. III-15a).  
 
Figure III-14: Caco-2 3D cultures are sensitive to Db-scTRAIL. Cells were grown in 3D or 2D in 
medium containing 10% FCS. (a) Three days post seeding, cultures were treated with Db-scTRAIL. 
Viability was measured 72 h later by MTT assay and normalized to the untreated control (N=3). 
(b) Phase contrast images of the 3D and 2D cultures described in (a) treated with the indicated 
concentrations of Db-scTRAIL for 72 h (scale: 50 µm).  
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Interestingly, in conventional 2D cell cultures on plastic, Caco-2 cells were highly resistant 
to Db-scTRAIL treatment (Fig. III-14a,b), in line with a previous report using recombinant 
human TRAIL [118].  
Pretreatment of the Caco-2 3D cultures with Z-VAD, a pan-caspase inhibitor, significantly 
reduced the cytotoxic effect of Db-scTRAIL (Fig. III-15b). The induction of apoptosis by Db-
scTRAIL was confirmed by the analysis of DNA fragmentation by Tunel staining 
(Fig. III-15c,d). Compared with 2D cultures, the dose-dependent activation of caspase 3/7 
in response to Db-scTRAIL was significantly increased in 3D cultures (Fig. III-15a).  
 
Figure III-15: Db-scTRAIL induces apoptosis in Caco-2 3D culture. Cells were grown in 3D or 2D in 
medium containing 10% FCS. (a) Three days post seeding, cultures were treated with 0.1 nM or 
1 nM Db-scTRAIL for 24 h. Caspase 3/7 activity was measured and normalized to the respective 
untreated control (ut) (N=3). (b) Three days post seeding, 3D cultures were pretreated with 
20 µM Z-VAD as indicated before addition of 1 nM Db-scTRAIL. Viability was measured 72 h later 
by MTT assay and normalized to the untreated control (ut) (N=3). (c) 24 h after treatment cells 
were fixed and stained for DNA strand breaks. Tunel-positive cells were counted (N=2). (d) 
Representative pictures of the Tunel stainings described in (c), Tunel-positive cells (red), DAPI 
(nuclei; blue). Shown are confocal sections (scale: 100 µm).  
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This difference in sensitivity toward Db-scTRAIL in 3D versus 2D cultures could not be 
attributed to changes in ErbB1 or TRAILR1/2 expression (Fig. III-16). Unfortunately, 
because the decoy receptors DcR1/DcR2 could not be detected by immunoblotting with 
the antibodies available, expression changes in these receptors could not be ruled out. 
Analysis of key signaling pathways revealed that, in 3D cultures, the activity of the PI3K 
pathway was suppressed compared with cells grown in 2D as measured by phospho-AKT 
levels whereas the ERK/MAPK pathway was upregulated as seen by increased ERK1/2 
phosphorylation (Fig. III-16). Additionally reduced expression levels of the anti-apoptotic 
protein cIAP2 were observable in Caco-2 cells grown in 3D cultures (Fig. III-16).  
 
Figure III-16: 3D culturing alters pro- and anti-apoptotic protein expression. Caco-2 cells were 
grown in 3D or 2D in medium containing 10% FCS. Four days post seeding, lysates were 
generated and analyzed by immunoblotting. Shown is one representative blot of three 
independent experiments. Tubulin was detected as a loading control. Specific bands are marked 
by arrowheads. 
However, inhibition of PI3K by LY294002 in 2D cultures was not sufficient to sensitize cells 
to Db-scTRAIL (data not shown), indicating a more complex scenario in 3D cultures. 
Together, these results underscore the impact of the culture conditions on the cellular 
response toward apoptosis-inducing agents. 
Db-scTRAIL activity is not limited by ErbB1 ligands 
ErbB1 activation not only stimulates cell proliferation but can also protect from TRAIL-
induced apoptosis [119]. Therefore, the efficacy of Db-scTRAIL was explored in the 
presence of ErbB1 ligands. Immunoblotting of lysates of EGF- and TGF-α-stimulated cells 
revealed a similar degree of suppression of ligand-induced ErbB1 phosphorylation by 
either cetuximab or Db-scTRAIL pretreatment (Fig. III-17a,c), indicating the efficient 
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competition of the diabody moiety with the ErbB1 ligands. This could also be confirmed in 
3D cultured Caco-2 cells stimulated with EGF (Fig. III-17b,d). Accordingly, EGF and TGF-α 
had no protective effect on viability in 3D (Fig. III-17e) nor were these ligands able to 
interfere with caspase activation (Fig. III-17f), demonstrating that Db-scTRAIL activity is 
not limited by the presence of ErbB1 ligands.  
 
Figure III-17: ErbB1 activation does not impair Db-scTRAIL activity. (a) Caco-2 cells grown in 2D 
were left untreated or treated with 4 nM Db-scTRAIL or 4 nM cetuximab for 15 min prior to 
stimulation with EGF or TGF-α (10 ng/ml) for 10 min. Phosphorylated and total proteins were 
detected by immunoblotting. Shown is one representative blot (N=3). Tubulin was detected as a 
loading control. (b) Immunoblotting of Caco-2 cells grown in 3D treated as in (a), shown is one 
representative blot (N=2). (c) Quantification of Western blots from (a). Phospho-ErbB1 levels 
were normalized to the corresponding total protein levels; levels in the untreated control were 
set as 1 (N=3). (d) Quantification of Western blots from (b) (N=2). (e,f) Three days post seeding, 
Caco-2 3D cultures grown in the absence or presence of growth factors were treated with 1 nM 
Db-scTRAIL. (e) Viability was determined by MTT assay after 72 h and normalized to the 
respective untreated control (ut). (N=3) (f) Caspase 3/7 activity was measured after 24 h. Values 
were normalized to the corresponding untreated control (ut) (N=3).  
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Importantly scTRAIL alone or in combination with cetuximab failed to elicit a cytotoxic 
response in Caco-2 3D cultures at all (Fig. III-18), supporting the previous data that the 
diabody-mediated dimeric structure of Db-scTRAIL confers superior bioactivity over 
scTRAIL [66].  
 
Figure III-18: Db-scTRAIL bioactivity is superior to scTRAIL plus cetuximab. Caco-2 cells were 
grown in 3D cultures in medium containing 10% FCS. (a,b) Three days post seeding, cultures were 
left untreated (ut) or treated with 1 nM Db-scTRAIL or 1 nM scTRAIL. (a) Cell viability was 
determined by MTT assay after 72 h and normalized to the untreated control (ut) (N=3). (b) 
Caspase 3/7 activity was measured after 24 h. The values shown were normalized to the 
untreated control (ut) (N=3). (c,d) Three days post seeding, cultures were left untreated (ut) or 
treated with 1 nM scTRAIL, 1 nM cetuximab or the combination of both. (c) Cell viability was 
determined by MTT assay after 72 h and normalized to the untreated control (ut) (N=3). (d) 
Caspase 3/7 activity was measured after 24 h. The values shown were normalized to the 
untreated control (ut) (N=3).  
To understand in more detail the resistance mechanisms toward Db-scTRAIL, re-isolated 
cysts from untreated and Db-scTRAIL-treated 3D matrigel cultures were analyzed by 
immunoblotting of cell lysates (Fig. III-19).  
Interestingly, lysates derived from surviving cysts (Fig. III-19a, arrows) revealed that these 
Db-scTRAIL-insensitive cells contained especially low ErbB1 levels. Of note, TRAIL receptor 
levels in these cells were similar to those in untreated cells, suggesting that the 
distribution of ErbB1 expression in the cell population strongly impacts Db-scTRAIL 
sensitivity (Fig. III-19b,c).  
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Figure III-19: ErbB1-directed targeting determines the bioactivity of Db-scTRAIL. (a) Three days 
post seeding Caco-2 3D cultures were either left untreated or treated with 5 nM Db-scTRAIL for 
72 h. Surviving cysts in the phase contrast images are indicated by arrows (scale: 50 µm). (b) 
Lysates derived from the 3D cultures shown in (a) were analyzed by immunoblotting. Shown is 
one representative blot of three independent experiments. Tubulin was detected as a loading 
control. Specific bands are marked by arrowheads. (c) Quantification of Western blots from (b). 
Protein levels were normalized to the corresponding tubulin control; levels in the untreated 
cultures were set as 1 (N=3). 
K-RasG12V expression induces Db-scTRAIL resistance in Caco-2 spheroids 
As mutated Ras renders cells insensitive to ErbB1 inhibition [70] and could impact TRAIL-
sensitivity [83], the effects of K-RasG12V expression on Db-scTRAIL induced cytotoxicity 
were determined. Therefore, 3D cultures of Caco-2tet K-RasG12V were treated with 
doxycycline for three days. Compared with the control cells, viability measurements 
revealed decreased sensitivity of oncogenic Ras expressing cells to Db-scTRAIL 
(Fig. III-20a). To confirm that this partial resistance was due to reduced apoptosis, Tunel 
stainings were performed and caspase 3/7 activation measured. Indeed, K-RasG12V cells 
showed strongly reduced DNA fragmentation after treatment with 1 nM Db-scTRAIL 
(Fig. III-20b) and only a weak induction of caspase activity (Fig. III-20c).  
This resistance was not due to ErbB1 or TRAILR1/2 downregulation (Fig. III-21). In fact, 
immunoblotting of 3D cell lysates of the vector and K-RasG12V cells revealed increased 
TRAILR2 protein levels (Fig. III-21a,b), in agreement with previous reports [83,84]. 
Oncogenic Ras can interfere with apoptosis at multiple levels, for example, by the 
activation of PI3K survival signaling pathway and changes in transcriptional programs 
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[81,82]. Indeed, in 2D cultures, increased AKT phosphorylation in K-RasG12V expressing cells 
was observable. 
 
Figure III-20: Oncogenic K-Ras protects Caco-2tet cells from Db-scTRAIL induced apoptosis. (a-c) 
Caco-2tet vector control and K-Ras
G12V
 cells were seeded into 3D cultures in the presence of dox. 
Three days later, cultures were treated with Db-scTRAIL. (a) Viability was measured 72 h later by 
MTT assay and normalized to the untreated control (N=3). (b) 24 h after treatment with 1 nM Db-
scTRAIL, cells were fixed and stained for DNA strand breaks. Tunel-positive cells were counted 
(N=2). (c) Caspase 3/7 activity was measured after 24 h treatment with 1 nM Db-scTRAIL. Values 
shown were normalized to the corresponding untreated control (ut) (N=3).  
In 3D cultures, however, the suppression of the PI3K/AKT pathway appears to be 
dominant (see Fig. III-16), with K-RasG12V expression leading to marginally elevated AKT 
phosphorylation only (data not shown). Interestingly, expression analysis of selected key 
regulators of the apoptotic machinery revealed significantly elevated levels of the anti-
apoptotic proteins cIAP2, FlipS, and Bcl-xL (Fig. III-21b).  
The upregulation of the anti-apoptotic protein cIAP2 was specific for the K-Ras mutation 
and could not be detected by active B-RafV600E mutation, providing evidence for an 
independent mechanism (Fig. III-21c). 
A smac mimetic sensitizes K-Ras mutated CRC cells to Db-scTRAIL treatment 
Because molecular changes occurred at different levels of the apoptotic pathway, blocking 
of K-RasG12V induced anti-apoptotic signaling as far downstream as possible seemed 
promising. Inhibitors of apoptosis (IAP) proteins, such as cIAP2, interfere with apoptosis by 
the direct binding, inhibition and/or degradation of caspases and components of the 
Ripoptosome, and by antagonizing non-canonical NFκB signaling [120]. The activity of IAP 
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proteins is balanced by Smac/Diablo, a protein released from mitochondria in cells primed 
for apoptosis. Peptides that mimic the aminoterminal IAP-binding sequence of Smac, so-
called Smac mimetics, were found to enhance the cytotoxicity of chemotherapeutic 
agents and death ligands such as TRAIL [121,122]. 
 
Figure III-21: Oncogenic K-Ras changes the pro- and anti-apoptotic protein balance. (a) 
Caco-2tet vector control and K-Ras
G12V
 cells were grown in 3D cultures in the presence of dox for 
4 days. Cells were recovered from the 3D cultures and lysates were analyzed by immunoblotting. 
Shown is one representative blot of three independent experiments. Tubulin was detected as a 
loading control. Specific bands are marked by arrowheads. (b) Quantification of Western blots 
from (a). Protein levels were normalized to the corresponding tubulin control; levels in the vector 
control were set as 1 (N=3). (c) Immunoblotting of Caco-2tet vector control, B-Raf
V600E 
and 
K-Ras
G12V
 cells as described in (a). Shown is one representative blot of two independent 
experiments. 
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Indeed, co-treatment of Caco-2tet K-RasG12V cells with Db-scTRAIL and a previously 
developed highly efficient dimeric Smac mimetic, SM83 [115,116], decreased cell viability 
by 35% compared with the single treatments. This was efficiently blocked by Z-VAD, 
proving the involvement of caspase activation in the case of the combinatorial treatment 
(Fig. III-22a). Tunel staining further confirmed the enhancement of apoptosis by SM83 
(Fig. III-22b).  
 
Figure III-22: The Smac mimetic SM83 overcomes the K-Ras
G12V
 induced Db-scTRAIL resistance. 
(a-c) Caco-2tet Ras
G12V
 cells were seeded into 3D cultures in the presence of dox. (a) Three days 
later, cultures were left untreated or treated with 5 µM SM83 or 20 µM Z-VAD for 1 h prior to 
addition of 1 nM Db-scTRAIL. Viability was measured 24 h later by MTT assay and normalized to 
the untreated control (N=3). (b) 24 h after treatment, cells were fixed and stained for DNA strand 
breaks. Tunel-positive cells were counted (N=2). (c) Three days post seeding, cultures were left 
untreated (ut) or treated with 5 µM SM83. Cells were recovered from the cultures 24 h later and 
lysates were analyzed by immunoblotting. Shown is one representative blot of two independent 
experiments. Tubulin was detected as a loading control. (d) Caco-2tet Ras
G12V
 cells grown in 2D 
for 72 h in the presence of dox followed by treatment with 5 µM SM83 for the indicated time 
points prior to lysis. Proteins were analyzed by immunoblotting using the indicated antibodies. 
Tubulin was detected as a loading control.  
Of note, the presence of SM83 also lowered the Db-scTRAIL concentration required to kill 
parental Caco-2 and Caco-2tet vector cells (data not shown). Analysis of cell lysates 
derived from Caco-2 3D cultures showed that SM83 incubation for 24 h led to the 
 III. RESULTS 
 
58 
 
complete loss of cIAP1, whereas cIAP2 levels were only slightly decreased and xIAP, 
survivin and Smac were not affected (Fig. III-22c). The presence of cIAP2 at this time point 
can be explained by its upregulation in response to cIAP1 loss in accordance with a 
previous report [123]. Indeed cIAP2 protein levels were initially downregulated, but come 
back to normal levels after 60 min of SM83 treatment (Fig. III-22d). Nevertheless, by 
regulating the overall IAP/Smac balance, SM83 appears to restore the apoptotic response 
in oncogenic Ras expressing Caco-2 cells. 
Finally, to investigate whether our targeted combinatorial strategy could be transferred to 
CRC cell lines with endogenous K-Ras mutations, co-treatment of HCT-116 and LoVo cells 
with Db-scTRAIL and SM83 in 3D cultures was performed. These cell lines are ErbB1-
positive (data not shown) and show moderate sensitivity to Db-scTRAIL, making them 
amenable to the combined action of Db-scTRAIL and Smac mimetics.  
 
Figure III-23: The Smac mimetic SM83 sensitizes oncogenic K-Ras expressing CRC cells to Db-
scTRAIL treatment. (a) HCT-116 and (b) LoVo cells were grown in 3D cultures for six days, and 
then fixed and stained for F-actin (red) and DNA (DAPI; blue) (scale: 20 µm) (top panels). Three 
days post seeding cultures were left untreated or pretreated with 5 µM SM83 prior to addition of 
0.05 nM Db-scTRAIL. Viability was measured 24 h later by MTT assay and normalized to the 
untreated control (bottom panels) (N=3). 
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Reminiscent of the Caco-2tet K-RasG12V cells, HCT-116 and LoVo cells failed to form 
differentiated and polarized spheroids in 3D culture (Fig. III-23a,b; upper panel). 
Importantly, a synergistic cytotoxic effect of Db-scTRAIL and SM83 was observed for both 
cell lines when Db-scTRAIL was applied at a sublethal concentration (Fig. III-23a,b; lower 
panel). Thus, based on these data I propose that ErbB1-targeted scTRAIL molecules, 
together with apoptosis-sensitizing agents, may be an effective therapy for CRC 
independently of the K-Ras status.  
In sum, using a 3D CRC cell culture model, in this thesis it was shown for the first time that 
K-RasG12V induced hyperproliferation, loss of polarized morphogenesis and escape from 
apoptosis, which are hallmarks of cancer cells, involve an ErbB3-dependent autocrine 
signaling loop on the one hand and the upregulation of anti-apoptotic proteins such as 
cIAPs on the other hand. Provided that the activation of these signaling pathways can also 
be observed in additional Ras-mutant CRC cell lines and in primary human CRC, these 
findings have important implications for the design of novel targeted treatment strategies 
of K-Ras mutant CRC.  
60 
I V .  D I S C U S S I O N
In this thesis, studies were performed in a matrix-dependent 3D model system of Caco-2 
cells because this model mimics important features of polarized epithelial organization 
that are not recapitulated in conventional 2D cell cultures. In addition, the tetOn system 
allowed the investigation of the immediate effect of K-RasG12V expression in the Caco-2 
model on cell proliferation and polarization. In the development of CRC, Ras mutations are 
preceded by mutations in APC associated with the activation of the WNT pathway and the 
formation of benign polyps [12]. Considering the frequent co-occurrence of APC and K-Ras 
mutations, Caco-2 cells are a suitable model for the analysis of the early molecular and 
cellular changes induced by Ras activation, as these cells harbor an inactivating mutation 
in APC, but they lack oncogenic alterations within the MAPK and PI3K pathway [88]. 
Because of the limitations in treatment of K-Ras mutated CRC patients with available 
blocking antibodies alone and the inevitable evolvement of resistance during anti-
proliferative treatment, induction of apoptosis in tumor cells via TRAIL seems to be an 
alternative strategy in treating CRC. Due to its selectivity for tumor cells, TRAIL is regarded 
as a promising anti-cancer therapeutic. Apoptosis induction by TRAIL moreover does not 
depend on p53, the frequent loss or mutation of which is a major cause of chemotherapy 
resistance. Despite these advantageous features of TRAIL, the molecular mechanisms that 
govern TRAIL sensitivity versus resistance still remain poorly understood. There is neither 
a clear correlation between total TRAILR1/2 levels nor the ratio of TRAILR1/2 and the 
decoy receptors DcR1, DcR2 and TRAIL sensitivity [124,125]; instead, activation of 
PI3K/AKT and NFκB signaling pathways, and the overexpression of anti-apoptotic proteins 
such as Bcl-2, IAPs and Flip have been implicated in TRAIL resistance [62,64,126].  
A better understanding of tumor development and progression as well as of resistance 
mechanisms and the identification of effective drug combinations are thus essential for 
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the right choice of target patients and an optimized personalized treatment design. 
Therefore I explored the effect of oncogenic K-Ras on initial steps of tumor development 
like hyperproliferation and polarization defects and furthermore investigated potential 
mechanisms of action of a targeted single-chain TRAIL molecule (Db-scTRAIL) comprising 
an ErbB1 blocking and targeting moiety derived from cetuximab and three TRAIL 
monomers in the 3D model of CRC. 
Impact of culture conditions on cell signaling 
The comparison of Caco-2 cells grown in 2D versus 3D culture revealed that the cellular 
environment not only affected morphology but also profoundly altered important 
signaling pathways, and therefore the balance between proliferation, survival and death. 
The most apparent changes in these hallmarks of cancer included the expression and/or 
activation levels in AKT, ERK and cIAP2. In 3D cultures, Caco-2 cells displayed dramatically 
increased sensitivity to Db-scTRAIL-induced apoptosis, whereas 2D cultured Caco-2 cells 
were highly resistant against Db-scTRAIL (Fig. III-14). The increased apoptotic potency in 
3D of this targeted TRAIL molecule can neither be explained by elevated levels of the 
target itself nor by elevated death receptor expression as no changes in ErbB1 or TRAIL1/2 
receptor levels were observable in 3D compared to 2D cultured Caco-2 cells. Another 
mechanism that could enhance targeting efficiency and/or the signaling capacity of the 
death receptors could be clustering of the receptors. The basolateral localization of ErbB1 
and the TRAIL receptors may create a more densely packed signaling platform that 
facilitates accumulation of Db-scTRAIL and therefore death receptor oligomerization and 
activation [47,127]. The subcellular localization of the ErbB receptors can play an 
important role as well. The regulation of ErbB2 signaling in polarized epithelia by 
relocation of the receptor to the apical surface after overexpression leads to changes in 
the signaling pattern towards survival via a Bcl-2 related pathway [128]. As all ErbB 
receptors are localized to the basolateral membrane in normal, differentiated tissues 
[129], the effect of relocation could be important for the other ErbB receptors as well and 
could be responsible for the signaling changes in the MAPK and PI3K cascades observed 
here. Unfortunately the ErbB receptors could not be detected by immunofluorescence 
staining in the 3D cultures to address their precise localization. 
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Polarized growth of Caco-2 cells in the presence of extracellular matrix components also 
altered the activation states of intracellular signaling pathways. In particular, the 
suppression of the PI3K pathway in Caco-2 3D cultures is likely to contribute to the 
enhanced TRAIL sensitivity, as activation of this pathway correlates with TRAIL resistance 
in several tumor cell lines and PI3K inhibition rendered cells more sensitive toward TRAIL 
treatment [48,130,131]. In addition to the changes in the PI3K pathway the 
downregulation of the anti-apoptotic protein cIAP2 probably adds to the observed Db-
scTRAIL sensitivity in the Caco-2 3D cell culture model. 
Regardless of the precise mechanism, the impact of the cell culture set-up seems to be 
tremendous and has to be considered in the translation of in vitro drug testing to in vivo 
studies. 
K-RasG12V induced TRAIL resistance 
In Caco-2tet cells inducibly expressing K-RasG12V, oncogenic K-Ras not only interfered with 
proper polarization but it also protected from death receptor-induced apoptosis in the 3D 
cultures (Fig. III-20). In CRC, ligand-independent activation of the ERK/MAPK and PI3K 
pathways by mutant K-Ras is associated with the loss of responsiveness to cetuximab [70] 
and additionally enhances cell proliferation and favors survival by interfering with the 
apoptotic machinery. Specifically, K-RAS mutations at codon 12 could be correlated with 
reduced apoptosis in vitro and lower apoptotic indices in colorectal tumors [132]. By 
contrast, K-Ras has also been reported to promote apoptosis through the upregulation of 
TRAILR2 [82,83]. Intriguingly, in the used doxycycline-treated Caco-2tet K-RasG12V cells 
TRAILR2 was also found to be upregulated, however, this was not sufficient to trigger 
apoptosis. It appears that the additional molecular changes in the apoptotic pathway 
downstream of TRAIL receptors, such as the elevation of FlipS, Bcl-xL and cIAP2, ultimately 
favor cell survival.  
Especially alterations in IAPs are found in many types of human cancer and associated 
with chemoresistance, disease progression and poor prognosis [120,133]. In intestinal 
epithelial cells, mutated Ras was shown to cause cIAP2 upregulation via a TGF-α autocrine 
loop [80]. This observation is consistent with the results obtained with the K-RasG12V 
expressing Caco-2 cells used here and further supports the potential benefit of blocking 
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autocrine ErbB1 signaling in combination with death receptor stimulation. cIAP proteins 
bind, but do not inhibit caspases 3 and 7, promoting their ubiquitination and degradation 
[127]. This explains the reduced caspase 3 levels observed in Caco-2tet RasG12V cells, 
although this downregulation was not significant. IAPs can be targeted and inhibited by 
Smac mimicking molecules. These Smac mimetics were originally developed to block xIAP, 
but they are most effective in triggering the auto-ubiquitination and degradation of cIAP1 
and cIAP2. In the 3D Caco-2 model, strongly reduced cIAP1 levels were detected 24 hours 
after SM83 treatment, whereas cIAP2 was only transiently downregulated, in accordance 
with the finding that cIAP1 downregulation causes cIAP2 upregulation by non-canonical 
NFκB activation [127]. Nevertheless, the potent downregulation of cIAP1 by SM83 appears 
to be sufficient to tip the balance and restore an apoptotic response to Db-scTRAIL 
treatment in three different CRC cell lines. Smac mimetics have further been reported to 
induce cytotoxicity as single agents, a feature linked to the induction of TNF-α synthesis 
and secretion [134,135]. However, in Caco-2, HCT-116 and LoVo cells, there was no 
cytotoxicity in response to SM83 alone, suggesting that the increased susceptibility to 
death receptor-induced apoptosis primarily stems from TRAIL receptor signaling. 
ErbB1 targeting in the context of K-RasG12V 
The efficient reduction of basal and ErbB1 ligand-induced proliferation of Caco-2 cells in 
3D cultures by Db-scTRAIL in addition to efficiently inducing apoptosis of ErbB1-positive 
cells irrespective of the presence of the ErbB1 ligands EGF or TGF-α clearly showed the 
biological activity of the anti-ErbB1 targeting moiety. Indeed, in an ErbB2 tumor mouse 
model the combined treatment with an ErbB2 blocking antibody and a TRAILR2 agonistic 
antibody had synergistic effects [136]. And as oncogenic K-Ras has also been associated 
with the increased expression and/or shedding of ErbB1 ligands such as TGF-α, 
amphiregulin and HB-EGF the blocking of ErbB1 in the presence of mutated K-Ras may be 
useful [29,30,86]. ErbB1 ligands further have been reported to protect epithelial cells from 
TRAIL-induced apoptosis, mainly via the activation of PI3K signaling [119,137]. Treatment 
of CRC cells with recombinant TRAIL was further reported to lead to ErbB1 upregulation 
and shedding of TGF-α, resulting in the activation of autocrine and paracrine ErbB1/HER2 
pro-survival signaling [86]. Additionally, ErbB1 ligand shedding may also be induced by 
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oncogenic Ras signaling [86] that could lead to paracrine activation of the surrounding 
cells, not necessarily carrying an active K-Ras mutation and therefore responding to ErbB1 
inhibition. These findings provide a rationale for combining pharmacological ErbB1 
blockade with TRAIL receptor agonists for treatment of K-Ras mutated CRC, although 
cetuximab itself is not recommended for K-Ras mutated tumors.  
A very important aspect uncovered by this study is the requirement for tumor cell-specific 
targeting of recombinant TRAIL to elicit a potent cytotoxic response. Intriguingly, cells 
surviving Db-scTRAIL treatment in the 3D cultures expressed very low ErbB1 levels. 
Although the diabody moiety does not actively contribute to apoptosis and mainly has a 
growth inhibitory function in Caco-2 3D cultures, the ErbB1-directed targeting is important 
to increase the local TRAIL concentration and to trigger an efficient apoptotic response. It 
can thus be assumed that patients whose tumors express high ErbB1 levels should 
respond best to Db-scTRAIL. Directing recombinant single-chain TRAIL molecules to tumor-
specific surface antigens using a diabody-based forced dimerization strategy is not limited 
to the ErbB1 and together with appropriate apoptosis sensitizing agents may be a 
powerful approach to efficiently kill a broad range of cancer cells.  
ErbB receptor ligands and polarization in the context of K-RasG12V 
Besides its impact on TRAIL sensitivity by upregulation of cIAP2 the expression of K-RasG12V 
also induced the transcriptional activation of HRG1/2, an ErbB3 specific ligand. The 
ablation of HRG1/2 in these cells restored both, normal proliferation and morphology of 
Caco-2 cells. By exogenous addition of HRG to Caco-2 and primary intestinal organoid 
cultures it was clearly shown that HRG-induced ErbB3 signaling is not compatible with 
intestinal epithelial organization. Apart from driving proliferation, HRG is a stimulator of 
cell migration and invasion as well as tumorigenicity and metastasis [19,24]. In the breast 
cancer cell line MCF-7, HRG leads to loss of cell-cell contacts by inducing breakdown of 
adherens and tight junctions dependent on the MAPK pathway [138]. By contrast, HRG-
ErbB2/3 signaling is crucial for the proper establishment of normal barrier function in the 
airway epithelium [139], showing again the cell context dependence of the impact of 
growth factor induced activation of the ErbB receptor pathways. The HRG-ErbB3 induced 
secretion of the growth factor VEGF in CRC cell lines and the correlation of HRG mRNA 
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expression with VEGF mRNA expression in colon cancer biopsy samples further shows the 
importance of this signaling axis in tumor establishment and progression also in the 
context of angiogenesis [140]. In the different CRC subtypes, however, there is still little 
known about the expression of ErbB3 and the ErbB ligands. Irrespective of cancer-
associated mutations in K-Ras, aberrant HRG production by the stromal compartment 
could also impact the integrity of the intestinal epithelium. In contrast to HRG, addition of 
ErbB1 ligands only enhanced the proliferation of Caco-2 and organoid cultures but did not 
interfere with polarized morphogenesis. This highlights the independent regulation of 
proliferation and polarity and the qualitatively distinct signaling characteristics of the 
different ErbB ligands.  
Although Ras directly activates PI3K [31], I would suggest that the autocrine HRG-ErbB3 
signaling loop is engaged to amplify PI3K activation and cooperates with constitutively 
active MAPK in cell transformation downstream of Ras. This is in line with Venkateswarlu 
et al. who found that in the colon cancer cell line GEO, growth factor independence and 
block of apoptosis generated by autocrine heregulin was based on AKT and not MAPK 
activation [141]. This idea is further corroborated by the observation that RTKs exert 
dominant control over PI3K signaling in K-Ras mutant CRC cells [142]. Although pan-ErbB 
inhibition did not lead to detectable suppression of pAKT levels in K-RasG12V expressing 
Caco-2 cells, the acute ectopic expression of mutated Ras in the 3D Caco-2 cell system 
may differ from the situation in established CRC cells harboring endogenous K-Ras 
mutations.  
Downstream effector pathways of the polarization defect in K-RasG12V cells  
Considering that AKT activation is strongly suppressed in Caco-2 3D cultures compared to 
2D monolayers the elevation of pAKT levels downstream of ErbB3 may contribute to the 
HRG-induced proliferation and/or polarity loss. However, in a previous report, the stable 
expression of activated PI3K in Caco-2 cells did not perturb 3D morphogenesis and PI3K 
inhibition failed to rescue the morphology or size of Caco-2 spheroids stably expressing 
mutant Ras [88].  
Of note, the Caco-2 cells used in the publications by Magudia et al., Drosopoulos et al. and 
Jaffe et al. [83,88,107] were all stably transfected with oncogenic K-Ras and could have 
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undergone pathway adaptions due to the selection process or the impact of the mutated 
KRAS gene itself. This might explain why elevated expression of c-myc after K-RasG12V 
expression, as described by Magudia et al., was not observed in the Caco-2tet K-RasG12V 
cells, suggesting also that the polarization defect observed here differs from the one 
described before [88]. This is also supported by the finding that the inducible expression 
of B-RafV600E did not lead to increased HRG or cIAP2 levels in the Caco-2 model system 
used here. As B-RafV600E expression in the Caco-2tet cells also results in polarization 
defects [143], the underlying molecular pathways triggered by constitutively active Ras 
and Raf appear to be distinct and suggest that further signaling pathways are required to 
stimulate proliferation and disrupt epithelial morphogenesis in Caco-2tet K-RasG12V cells.  
For example, in pancreatic adenocarcinoma, both PI3K and Stat3 activation downstream 
of ErbB1 were found to be essential for Ras-induced transformation [144]. In further 
experiments it could also be shown, that long-term stimulation with HRG lead to the 
activation of the Stat3 pathway in the 3D cultured Caco-2 cells used here [112]. This 
supports the involvement of other pathways like c-Met (hepatocyte growth factor 
receptor) signaling, also a RTK, or ErbB4 activation. It has been shown that pairing of c-
Met with ErbB3 plays an important role in CRC cell lines and c-Met overexpression is 
observed in various cancer types [95,145]. This signaling platform serves as an alternative 
pathway to ErbB2/ErbB3 signaling. In K-Ras mutated CRC cell lines c-Met signaling was 
also described as the main driver in resistance to MEK inhibition [87]. In addition, 
expression of c-Met correlates with cetuximab resistance in patient derived xenografts 
and inhibition of this RTK added to the anti-proliferative effect of cetuximab [146].  
ErbB3, a promising target in CRC 
Despite its impaired kinase activity, ErbB3 has attracted growing attention due to its 
emerging role in survival signaling and as a mediator of drug resistance by circumventing 
the targeted pathway [22,23] or, as ErbB3 is not targeted by common TKIs, by restoring 
the signaling pathways of the originally inhibited RTK by serving as an alternative 
dimerization partner [147]. At the molecular level this is primarily associated with the 
potent induction of the PI3K pathway. The important function in linking RTK and PI3K 
activation is best described in breast cancer, where the ErbB2-ErbB3 signaling dimer was 
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shown to be essential for tumor formation and maintenance [89,148,149]. Recently, 
somatic mutations in ErbB3 with transforming potential were reported in colon and gastric 
cancers, however, these variants were still functionally dependent on ErbB2 [25]. 
Although ErbB2-ErbB3 is regarded as the most potent ErbB dimer, ErbB3 also dimerizes 
with ErbB1 and non-ErbB family RTKs such as c-Met [145]. It is also discussed that ErbB3 
homo-dimers can sufficiently transactivate the receptor upon ligand binding [150]. An 
intestinal-specific ErbB3 knockout mouse model showed that the loss of ErbB3 resulted in 
loss of the ErbB4 protein, indicative of the formation of active ErbB3/4 signaling units 
[151]. Interestingly, when crossed to ApcMin mice, ErbB3 loss almost completely prevented 
colonic tumorigenesis, underscoring the important role of ErbB3 signaling in tumor 
establishment and progression [151]. The promiscuous pairing of ErbB3 with other RTKs 
like c-Met may explain why the single knockdown of ErbB1 or ErbB2 did not mirror the 
effects of ErbB3 depletion in the Caco-2tet K-RasG12V cells. As residual ErbB2 in siRNA-
treated cells could be sufficient to transactivate ErbB3, it cannot be ruled out that ErbB2 is 
the heterodimerization partner in this setting, in line with a report showing, that 
disproportionate ErbB2 levels efficiently activate ErbB3 [152]. The fact that ErbB3 
phosphorylation was below the detection limit upon K-RasG12V induction in Caco-2 cells 
further indicates that a low number of activated receptors suffices in the cooperative 
signaling with oncogenic Ras.  
Expression of ErbB3 in CRC was found to correlate with poorer overall survival and disease 
stage [92,93] and as revealed with higher tumor grade [112]. Tumor de-differentiation is a 
major prognostic factor, correlating with the risk of developing metastasis. Currently, 
several ErbB3-directed antibodies targeting the extracellular domain of the receptor are in 
clinical development [153]. A subset of CRC patients with Ras wild-type tumors fail to 
show an initial response to anti-ErbB1 therapy, whereas those that do respond routinely 
develop resistance, often by selection of Ras mutant clones. In such patients elevated 
circulating HRG levels were associated with both de novo and acquired resistance to 
cetuximab therapy [90]. Several reports describe the upregulation of ErbB3 as an evasion 
strategy to RTK inhibition [147,154,155] and pharmacologic MEK inhibition downstream of 
mutant Ras also unleashes feedbacks at the level of RTKs, including ErbB3 [79,156]. Thus, 
 IV. DISCUSSION 
 
68 
 
combinatorial treatments involving ErbB3 may be particularly effective for the treatment 
of Ras mutant CRC and may also prevent HRG-mediated resistance in Ras wild-type CRC. 
Outlook 
As the dimerization partner of ErbB3 involved in hyperproliferation and the observed 
polarization defects could not be defined, dual targeting strategies would be more 
insightful in future studies. A bi-specific antibody targeting ErbB1/3 or ErbB2/3 could be 
more efficient and could eventually help to answer who is the favorable dimerization 
partner of ErbB3 in this specific setting.  
As the targeting and dimerization effect of the Db-scTRAIL seems to be the most 
important factor in efficient delivery and apoptosis induction, a new rational targeting 
strategy for K-Ras mutated CRC could be the targeting of ErbB3 receptor. Further 
combination with a sensitizing smac mimetic could lead to efficient induction of apoptosis 
in K-Ras mutated cancer and significant inhibition of hyperproliferation and 
transformation processes like depolarization.  
In future studies it will be of great importance to not only analyze the mutational status of 
the tumor itself but also the signaling profiles and transcriptional programs in the 
surrounding tissue to evaluate the effect of paracrine signaling. Even if the inhibition of 
the induced growth factor signaling does not affect Ras mutated cells directly, blocking of 
proliferative signals in the surrounding tissue could efficiently contribute to treatment 
success. Additionally the effect of the observed HRG upregulation towards other tumor 
associated pathways like angiogenesis and metastasis could be blocked by an ErbB3 
targeted approach. The expression levels of these ErbB related ligands could be of great 
importance concerning the right treatment decision. The ligands strongly impact the 
efficiency of the specific targeting subunit of combined strategies. In accordance with the 
principle of a modular construction system the targeting components must be adjusted to 
the molecular profile of the tumor and the microenvironment to efficiently interrupt the 
oncogenic signaling pathways in the heterogeneous setting of cancer.  
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